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Abstract 
Genetic studies robustly implicate perturbation of DLG2-scaffolded mature postsynaptic 
signalling complexes in schizophrenia. Here we study in vitro cortical differentiation of DLG2-
/- human embryonic stem cells via integrated phenotypic, gene expression and disease genetic 
analyses. This uncovers a developmental role for DLG2 in the regulation of neural stem cell 
proliferation and adhesion, and the activation of transcriptional programs during early 
excitatory corticoneurogenesis. Down-regulation of these programs in DLG2-/- lines delays 
expression of cell-type identity and causes marked deficits in neuronal migration, morphology 
and active properties. Genetic risk factors for neuropsychiatric and neurodevelopmental 
disorders converge on these neurogenic programs, each disorder displaying a distinct pattern 
of enrichment. These data unveil an intimate link between neurodevelopmental and mature 
signalling deficits contributing to disease - suggesting a dual role for known synaptic risk genes 
- and reveal a common pathophysiological framework for studying the neurodevelopmental 
origins of Mendelian and genetically complex mental disorders. 
 
Keywords 
DLG2, neurogenesis, cortical differentiation, RNAseq, GWAS, rare variant, schizophrenia, 
autism, psychiatric genetics 
 
Introduction 
The aetiology of schizophrenia (SZ) has long been recognised to possess a developmental 
component based upon observational studies of anatomical differences (brain structural and 
cytoarchitectural changes and minor physical abnormalities); premorbid cognitive and motor 
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symptoms; and pre-natal environmental risk factors (Murray and Lewis, 1987; Weinberger, 
1987; Harrison, 1997, 1999). More recently large-scale genotyping studies have provided 
additional support, revealing substantial overlap between variants contributing to SZ liability 
and those conferring risk for other neurodevelopmental disorders including intellectual 
disability/severe neurodevelopmental delay (ID/NDD), autism spectrum disorders (ASD) and 
attention-deficit/hyperactivity disorder (ADHD) (Purcell et al., 2009; Sebat et al., 2009; Willia-
ms et al., 2010; Girirajan et al., 2012; Rees et al., 2014; Anttila et al., 2018). 
 
Despite compelling evidence for their existence, little is known concerning the pre-natal 
neurodevelopmental processes disrupted in SZ beyond the fact that they are likely to occur 
early in the second trimester of pregnancy (Harrison, 1997; Hill and Bray, 2012; Clifton et al., 
2019). Recent evidence suggests that many common genetic risk factors may impact gene 
expression in the mid-foetal brain (Walker et al., 2019) and are enriched in cell-types at 
multiple stages of cortical excitatory neuron development (Polioudakis et al., 2019). This 
raises the question: do common SZ variants converge on specific gene expression 
(transcriptional) programs that are activated or repressed during cortical excitatory neuron 
development in the mid-foetal brain? Mutations disrupting key regulators of such programs 
would be expected to possess a higher contribution to disease risk, reflected in a larger effect 
size and lower allele frequency. We therefore sought rare single-gene mutations linked to SZ 
where the affected gene is expressed in mid-foetal brain and has the potential to regulate 
transcriptional changes. This led us to DLG2. Independent de novo deletion events within 
DLG2 have been found in SZ patients (Kirov et al., 2012); recurrent deletions in the promoter 
of DLG2 are also implicated in ASD (Ruzzo et al., 2019). In humans, DLG2 mRNA is present 
from 8 weeks post-conception (Kang et al., 2011) as well as in vitro throughout all stages of 
differentiation from human embryonic stem cells (hESCs) to cortical projection neurons (van 
de Leemput et al., 2014). DLG2 is required for the formation of NMDA receptor complexes as 
synapses mature (Frank et al., 2016): these complexes regulate activation of transcriptional 
programs underlying long-term changes in synaptic function and are enriched for rare 
mutations found in SZ cases (Kirov et al., 2012; Fromer et al., 2014; Purcell et al., 2014; 
Szatkiewicz et al., 2014; Pocklington et al., 2015; Genovese et al., 2016). This raises the 
possibility that DLG2 may also be required for the formation of signalling complexes 
regulating early neurodevelopmental expression programs disrupted in SZ. 
 
To investigate its role in neurodevelopment we engineered homozygous loss-of-function 
DLG2 mutations into hESCs using the CRISPR-CAS9 system. Mutant (DLG2-/-) and isogenic 
sister wild-type (WT) hESC lines were differentiated into cortical excitatory neurons using a 
modified dual SMAD inhibition protocol (Chambers et al., 2009; Cambray et al., 2012) (Figure 
1A, B). Cells were extensively characterised at days 15, 20, 30 and 60 to identify phenotypes 
and expression programs altered in DLG2-/- lines and investigate their disease relevance 
(Figure 1A, B). 
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Results 
Knockout generation and validation 
Two DLG2-/- lines were created from H7 hESCs using the CRISPR/Cas9-D10A nickase system 
targeting the first PDZ domain (Figure S1). Sequencing revealed no off-target mutations (see 
Methods, Figure S2 & Table S1). A significant decrease in DLG2 mRNA was observed for exons 
spanning the first PDZ domain, with a similar decrease inferred for PDZ-containing transcripts, 
indicating degradation of DLG2-/- transcripts via nonsense-mediated decay (Figure S3A, B). 
Quantitative mass spectrometry-based proteomic analysis of peptide-affinity pulldowns using 
the NMDA receptor NR2 subunit PDZ peptide ligand (Husi and Grant, 2001) confirmed the 
presence of DLG2 in pulldowns from WT but not DLG2-/- lines (Figure S3C-F & Table S2). 
Genotyping revealed no CNVs in either DLG2-/- line relative to WT (Figure S4A). Both DLG2-/- 
lines expressed pluripotency markers OCT4, SOX2 and NANOG at 100% of WT levels (Figure 
S4B-E). Cells were extensively characterised for their cortical identity using western blotting 
and immunocytochemistry from day 20 to 60 (Figure S5). Over 90% of day 20 cells were 
positive for FOXG1, PAX6 and SOX2 confirming their dorsal forebrain fate (Figure S5A-B). 
 
DLG2 regulates neural stem-cell proliferation and adhesion 
RNA was extracted in triplicate from each line at 4 timepoints spanning cortical excitatory 
neuron development (Figure 1A, B) and gene expression quantified. To robustly identify genes 
dysregulated by DLG2 knockout, expression data from the 2 DLG2-/- lines were pooled and 
compared to a WT sister line at each timepoint (see Methods). Disruption of DLG2 had a 
profound effect: of the >13,000 protein-coding genes expressed at each timepoint, ~7% were 
differentially expressed between DLG2-/- and WT at day 15, rising to 40-60% between days 20 
and 30 then decreasing to ~25% by day 60 (Figure 1C). Strikingly, the 3 genes with the 
strongest evidence for differential expression at day 15 were from the same family of 
transcriptional regulators: ID1, ID3 and ID2 (Figure 1D). ID1-3 expression increases 
proliferation of cortical neural stem cells (NSCs) while inhibiting differentiation and 
maintaining adhesion to extracellular matrix (ECM) proteins (Jung et al., 2010; Niola et al., 
2012). Also highly perturbed at days 15 and 20 was expression of COL1A1 (Figure 1D, Table 
S3): this encodes the pro-ɲ ? ĐŚĂŝŶ ŽĨ ƚǇƉĞ / ĐŽůůĂŐĞŶ, an important ECM component in 
developing cortex (Long et al., 2018). To evaluate whether the wider set of genes differentially 
expressed in early proliferating cell-types (day 15 NSCs, day 20 NPCs) also highlight biological 
processes related to proliferation and ECM adhesion, we performed annotation over-
representation tests using Gene Ontology (GO) terms (see Methods). Compared to all genes 
expressed at one or more timepoint in DLG2-/- or WT lines (allWT+KO), those up-regulated at 
days 15 and 20 were over-represented in terms related to proliferation, differentiation, ECM 
composition and the regulation of ECM adhesion (Table S4) supporting dysregulation of these 
processes. Reasoning that changes in protein level typically lag those in mRNA we sought to 
validate these phenotypes in day 26 neural precursor cells (NPCs), also assaying day 0 (i.e. 
non-neural) hESCs as a negative control. We predicted that DLG2-/- cell-lines (in which ID1-3 
mRNAs are increased, Figure 1D) would exhibit increased proliferation and increased 
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adhesion to ECM proteins. DLG2-/- cells displayed increased adhesion to ECM protein 
substrates (Figure 1E, S6A) including type I collagen (highlighted by our expression analysis, 
Figure 1D) and fibronectin, a known mediator of ID-regulated adhesion (Niola et al., 2012). 
Proliferation did not differ between WT and DLG2-/- lines maintained as hESCs (Figure 1F), 
while day 26 NPCs from DLG2-/- lines exhibited significantly increased proliferation (Figure 1G, 
S6B). These data robustly confirm our predictions, illustrating that expression analyses 
identify true cell-biological changes. 
 
Common risk variants implicate disruption of neurogenesis in SZ 
We next sought to identify timepoints at which genes differentially expressed in DLG2-/- lines 
are enriched for SZ common risk variants. Taking summary statistics from the largest available 
SZ GWAS (Pardiñas et al., 2018), we utilised the competitive gene-set enrichment test 
implemented in MAGMA (version 1.07) (de Leeuw et al., 2015). As expected, allWT+KO was 
highly enriched for common variant association (P = 2.1 x 10-17) reflecting the neural lineage 
of these cells. We therefore tested genes up- and down-regulated at each timepoint for 
genetic association conditioning on allWT+KO using the strict condition-residualize procedure 
(all subsequent GWAS enrichment tests were conditioned on allWT+KO in the same way). This 
revealed strong association enrichment solely in genes down-regulated at day 30 (30down-/-: 
Pcorrected = 1.9 x 10-7, Figure 2A), coinciding with active neurogenesis (Figure 1B). This suggests 
that common variant perturbation of earlier (day 15-20) expression programs impacting NSC 
proliferation and ECM adhesion is not central to disease pathophysiology.  30down-/- genes 
were over-represented in GO terms related to neuronal development, function and migration 
(Table S5). Iterative refinement via conditional analyses identified 23 terms with independent 
evidence for over-representation (Figure 2B) (see Methods). This suggests that loss of DLG2 
dysregulates transcriptional programs underlying neurogenesis (neuronal growth, active 
properties and migration) and implicates these processes in SZ aetiology.  
 
Dysregulation of neurogenesis in DLG2-/- lines delays cell-fate determination 
To validate disruption of neurogenesis in DLG2-/- lines and investigate whether this leads to 
differences in the number or type of neurons produced, we compared the expression of cell-
type specific markers in DLG2-/- and WT lines from days 30-60 via immunocytochemistry (ICC) 
and Western blotting (Figure 2C-I). From ICC it was clear that DLG2-/- cells are able to 
differentiate and produce postmitotic neurons expressing characteristic neuronal markers 
such as NEUN (Figure 2F),  TUJ1 (Figure S5C) plus cortical deep layer markers TBR1 and CTIP2 
and upper layer marker SATB2. Western blot of NEUN (Figure 2C) and MAP2 (Figure S5D) and 
quantification of NEUN+ cells following ICC (Figure 2F) revealed no difference in the 
percentage of neurons produced by DLG2-/- cultures. This is in line with the comparable 
percentage of cells in the cell cycle/neural progenitors at days 30 to 60 in DLG2-/- and WT 
cultures indicated by a similar proportion of KI67+ and SOX2+ cells (Figure S5E-G). A similar 
analysis of layer markers TBR1, CTIP2 and SATB2 revealed a significant decrease in CTIP2+ cells 
but a comparable proportion of TBR1+ and SATB2+ neurons for all timepoints investigated 
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(Figure 2D-E, G-I, Figure S5H-I). On average the proportion of CTIP2+ cells in DLG2-/- recovered 
from 15% of the WT level on day 30 to 50% by day 60, although there was notable variation 
between DLG2-/- lines (Figure S6C-E); total CTIP2 protein level also recovered to some extent, 
but at a slower rate (Figure S6F-H). Thus DLG2-/- does not affect the rate at which neurons are 
produced but delays the expression of subtype identity in new-born deep layer neurons. 
 
DLG2-/- lines display deficits in neuron morphology & migration 
Given the over-representation of 30down-/- genes in terms related to neuron morphogenesis 
and migration (Figure 2B), we sought to experimentally validate these phenotypes. Immature 
(day 30) and mature (day 70) neurons were traced and their morphology quantified (Figure 
3). At both timepoints DLG2-/- neurons displayed a simpler structure than WT, characterised 
by a similar number of primary neurites projecting from the soma (Figure 3A) but with greatly 
reduced branching (Figure 3B). Total neurite length did not differ (Figure 3C), leading to a 
clear DLG2-/- phenotype of longer and relatively unbranched primary neurites (Figure 3E).  
There was no significant difference in soma area (Figure 3D). Day 40 DLG2-/- neurons had a 
slower speed of migration (Figure 3F) and reduced displacement from their origin after 70 hrs 
(Figure 3G-H). In summary, DLG2-/- neurons show clear abnormalities in both morphology and 
migration, validating the GO term analysis.  
 
Distinct transcriptional programs regulated by DLG2 are enriched for common SZ risk alleles 
DLG2 knockout has a profound impact on neurogenesis (growth, migration and expression of 
cell-type identity), down-regulating the expression of genes enriched for common SZ risk 
variants. We postulated that loss of DLG2 inhibits activation of transcriptional programs 
driving neurogenesis, which starts between days 20 and 30 and steadily increases thereafter. 
If this is the case, then SZ genetic enrichment in 30down-/- should be captured by genes 
normally upregulated between days 20 and 30 in WT cultures (20-30upWT). Analysing 
differential expression between WT samples at successive timepoints we found strong risk 
variant enrichment in 20-30upWT (Figure 4A). The overlap between 20-30upWT and 30down-/- 
captured the signal in both sets (Poverlap = 3.23 x 10-10; 30down-/- only P = 0.44; 20-30upWT only P 
= 0.62). This was not simply due to the size of the overlap (3075 genes, 85% of 20-30upWT) as 
the regression coefficient for the set of overlapping genes  ?ɴA? ? ? ? ? ) ?ǁŚŝĐŚƌĞĨůĞĐƚƐŵĂŐŶŝƚƵĚĞ
of enrichment, was significantly greater than for genes unique to 30down-/-  ?ɴA? ? ? ? ? ? ?Wdifferent 
= 0.0015) or 20-30upWT  ?ɴA?-0.015, Pdifferent = 0.0045). Thus, it is neurogenic transcriptional 
programs down-regulated in DLG2-/- lines that are enriched for SZ common variants. 
 
To more precisely identify SZ-relevant transcriptional programs active during neurogenesis, 
we classified 20-30upWT genes based on their subsequent WT expression profiles (Figure 4B, 
see Methods): early-increasing genes whose expression continues to rise between days 30 
and 60; early-stable genes whose expression stays at a relatively constant level; and early-
transient genes whose expression is later downregulated. We also defined a set of late genes, 
whose expression only increases significantly after day 30. These were further partitioned 
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into genes that were down-regulated at day 30 in DLG2-/- lines (e.g. early-stable-/-) and those 
that were not (e.g. early-stableWT only). The sole exception to this was the late set, which had 
minimal overlap with 30down-/- (62 out of 1399 genes) and was therefore left intact. Early-
stable-/- and early-increasing-/- sets were robustly enriched for SZ association (conditioning on 
allWT+KO, Figure 4C), revealing that association is restricted to 2 distinct transcriptional 
programs normally activated during the onset of neurogenesis but down-regulated in DLG2-/- 
lines. 
 
To confirm the existence of SZ-relevant transcriptional programs in vivo we repeated our 
derivation of early- and late programs using single-cell expression (scRNAseq) data from 
human foetal cortex (Nowakowski et al., 2017), mapping the principal cell-types present at 
each timepoint in culture (Figure 1B) onto sub-types identified in vivo (see Methods). Despite 
the notably reduced gene/transcript coverage of existing scRNAseq technologies, we 
confirmed that SZ association was restricted to early-stable and early-increasing programs. 
Effect sizes were closely comparable between in vitro and in vivo programs (Figure 4C-D). 
 
A cascade of transcriptional programs drives neurogenesis & differentiation 
We next investigated the biological function of the 4 main programs identified in vitro: early-
transient-/-, early-stable-/-, early-increasing-/- and late. Each was over-represented for a 
coherent set of GO terms indicating a distinct biological role (Table S6): early-transient-/- for 
histone/chromatin binding and transcriptional regulation; early-stable-/- for signal 
transduction, transcriptional regulation, neurogenesis, cell projection development, 
migration and differentiation; early-increasing-/- for axon guidance, dendrite morphology and 
the establishment of synaptic connections and active properties; and late for mitochondrial 
energy production, peptide synthesis/transport, synaptic signalling and the regulation of ion 
homeostasis linked to synaptic transmission. 
 
The distinct biological roles of the 3 early- programs prompted us to hypothesise that they 
form a linked, time-ordered cascade of transcriptional programs triggered at the onset of 
neurogenesis. This begins with an initial phase of chromatin remodelling as NPCs exit the cell-
cycle and commit to a neuronal fate (early-transient-/-), activating a longer-term program 
guiding cell growth and migration (early-stable-/-). This, in turn, promotes the fine-tuning of 
cell-type specific neuronal structure, function and connectivity as cells enter the terminal 
phase of differentiation (early-increasing-/-). 
 
To investigate support for this regulatory cascade we identified key regulators from each 
program whose downstream targets have been experimentally identified or computationally 
predicted (see Methods): chromatin modifier CHD8 from early-transient (Sugathan et al., 
2014; Cotney et al., 2015); transcription factor TCF4 and translational regulator FMRP from 
early-stable-/- (Forrest et al., 2018, Darnell et al., 2011); and transcription factors (and deep 
layer markers) TBR1 and BCL11B (CTIP2) from early-increasing-/- (Wang et al., 2018). We 
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predicted that a substantial proportion of early-stable-/- genes would be directly regulated by 
CHD8, while early-increasing-/- would be enriched for genes directly regulated by TCF4, TBR1 
and BCL11B. Since early-transient-/- is responsible for activating later programs, we predicted 
that early-increasing-/- would be enriched for indirect targets of CHD8 (genes not directly 
regulated but whose expression is altered when CHD8 is perturbed) that are down-regulated 
in CHD8 knockdown cells (Sugathan et al., 2014). We also predicted that early-transient-/- 
genes would not be enriched for targets of terminal phase regulators BCL11B and TBR1. FMRP 
represses the translation of its mRNA targets, facilitating their translocation to distal sites of 
protein synthesis (Krichevsky and Kosik, 2001; Darnell et al., 2011), and its function is known 
to be important for axon and dendrite growth (Antar et al., 2006). We therefore predicted 
that early-stable and -increasing (but not -transient) genes would be enriched for FMRP 
targets. Over-representation tests emphatically confirmed these predictions (Figure 4E). In 
addition, the targets of TCF4, FMRP, BCL11B and TBR1 were more highly enriched for SZ 
association than other genes in early-increasing-/- (Figure 4E), indicating an important role for 
these regulators in disease. 
 
Convergence of genetic risk on perturbed action potential generation 
We next tested whether biological processes over-represented in early-stable-/- or early-
increasing-/- (Table S6) captured more or less of the SZ association in these programs than 
expected (see Methods). None of the 13 semi-independent GO term subsets identified in 
early-stable-/- differed substantially from early-stable-/- as a whole (Table S7), indicating that 
risk factors are distributed relatively evenly between them. Of the 16 subsets for early-
increasing-/-, somatodendritic compartment and membrane depolarization during action 
potential displayed evidence for excess enrichment relative to the program as a whole (Figure 
4F). Again, no single term showed evidence for depletion, suggesting that diverse biological 
processes regulating neuronal growth, morphology and function are perturbed in SZ. The 
enhanced enrichment in action potential (AP) related genes is particularly striking: while 
complexes regulating postsynaptic information processing have been robustly implicated in 
disease, this represents the first evidence that electrical properties underlying information 
transmission are also disrupted.  We therefore sought to confirm the disruption of APs in 
DLG2-/- lines (Figure 5A-K), also investigating the impact of DLG2 loss on synaptic transmission 
(Figure 5L-N). 
 
Day 50 DLG2-/- neurons were less excitable, with a significantly more depolarised resting 
membrane potential (Figure 5A). Stepped current injection evoked AP firing in 80% WT but 
only 43% DLG2-/- neurons (Figure 5C). APs produced by DLG2-/- cells were characteristic of less 
mature neurons (Figure 5D), having smaller amplitude, longer half-width and a slower 
maximum rate of depolarisation and repolarisation (༬V/༬t) (Figure 5E-H). We found no 
change in AP voltage threshold, rheobase current (Figure 5I-J) or input resistance (Figure 5B). 
The percentage of neurons displaying spontaneous excitatory postsynaptic currents (EPSCs) 
was comparable at days 50 and 60 (Figure 5N) as was EPSC frequency and amplitude (Figure 
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5L-M). Lack of effect on synaptic transmission may reflect compensation by DLG4, whose 
expression shows a trend towards an increase in synaptosomes from day 65 DLG2-/- neurons 
(Figure 5O). In summary, DLG2-/- neurons have a reduced ability to fire APs and produce less 
mature APs. 
 
Loss-of-function intolerant genes enriched for common risk variants localise to developmental 
transcriptional programs 
Genes intolerant to loss-of-function mutations (LoFi genes) are highly enriched for SZ GWAS 
association (Pardiñas et al., 2018). However, it is not known when or where in development 
they exert their effect. We predicted that LoFi genes would primarily be concentrated in 
earlier transcriptional programs (early-transient-/-, early-stable-/-) where the impact of 
disruption is potentially more severe. LoFi genes were over-represented in both of these and 
also early-increasing-/- (Figure 6A). LoFi GWAS association (conditioned on allWT+KO) was 
largely captured by the overlap with early-stable-/- and early-increasing-/- sets, localising 
genetic risk factors to roughly one third of LoFi genes and providing a clear biological context 
for their action (Figure 6B). 
 
Rare and common SZ risk variants converge on common neurodevelopmental pathways 
We next tested each program for enrichment in rare SZ mutations. Compared to all expressed 
genes (allWT+KO), both de novo and singleton LoF mutations were enriched in early-stable-/-. 
Early-increasing-/- displayed a trend towards enrichment in LoF singleton mutations only 
(Figure 6C-D). This provides independent genetic evidence for disruption of transcriptional 
programs regulating neurogenesis in SZ. 
 
Risk variants for other neuropsychiatric disorders display distinct patterns of enrichment 
Finally, we interrogated transcriptional programs for enrichment (relative to allWT+KO) in 
variants conferring risk for different disorders. Early-transient-/-, -stable-/- and -increasing-/- 
sets had an increased rate of de novo LoF mutations contributing to NDD and ASD 
(Satterstrom et al., 2019) (Figure 6E). Comparing the magnitude of the increase, a clear 
gradient was evident from NDD to ASD to SZ (Figure 6F). LoF mutations from unaffected 
siblings of individuals with ASD (Satterstrom et al., 2019) showed no evidence for an increased 
rate in any of the sets tested (Figure 6E-F). ADHD common variants (Demontis et al., 2019) 
were enriched in early-increasing-/- and there was a modest enrichment for bipolar disorder 
(BIP) common variants (Stahl et al., 2019) in early-stable-/- (Figure 6G-H). In contrast, common 
variants conferring risk for neurodegenerative disorder ůǌŚĞŝŵĞƌ ?ƐĚŝƐĞĂƐĞ ?) (Lambert et 
al., 2013) were not enriched in any program (Figure 6G-H). Dysregulation of neurogenesis 
thus contributes to a wide spectrum of neuro-developmental/-psychiatric disorders, each 
displaying a distinct profile of risk variant enrichment across neurogenic transcriptional 
programs (Figure 6F,H). 
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Discussion 
A complex choreography of cell proliferation, specialisation, growth, migration and network 
formation underlies brain development. To date, limited progress has been made pinpointing 
aspects of this process disrupted in neurodevelopmental disorders. Here we demonstrate 
that DLG2 - in addition to its role as a postsynaptic scaffold protein - regulates neural stem 
cell proliferation and adhesion and the activation of transcriptional programs underlying early 
corticoneurogenesis that are enriched for genetic risk factors contributing to a wide range of 
disorders (Figure 7). It has been proposed that adult and childhood disorders lie on an 
aetiological and neurodevelopmental continuum: the more severe the disorder the greater 
the contribution from rare, damaging mutations and the earlier their developmental impact 
 ?ƌĂĚĚŽĐŬĂŶĚKǁĞŶ ? ? ? ? ? ?KǁĞŶĞƚĂů ? ? ? ? ? ? ?KǁĞŶĂŶĚK ?Ž ŽǀĂŶ ? ? ? ? ? )(Figure 7B).  Our 
data support this model and ground it in developmental neurobiology (Figure 6E-H), 
embedding genetic risk for multiple disorders in a common pathophysiological framework. 
 
Novel role for DLG2 in early corticoneurogenesis  
The birth of neurons during CNS development is a sequential process involving the generation 
of progressively more specialised cell-types. Proliferating neuroectodermal cells (NSCs) in the 
neural tube give rise to neural precursors (NPCs): radial glia (RG) and intermediate 
progenitors (iPCs). Both RG and iPCs have a limited ability to proliferate, with RG giving rise 
to neurons either directly or via iPCs.  In the cortex, excitatory neurons in layers VI-II are born 
in a sequential, inside-out fashion (from deep to upper layers), with early-born post-mitotic 
cells becoming deep layer (VI, V) neurons. This process is broadly recapitulated by in vitro 
differentiation protocols (e.g. Figure 1B), with neurons produced between our day 30 and 60 
timepoints predominantly displaying a deep layer identity. 
 
NPCs from DLG2-/- lines exhibit increased proliferation but do not significantly differ in terms 
of the differentiation timepoint at which they start to commit to a neuronal fate or the 
subsequent rate at which neurons are generated. This indicates that loss of DLG2 leads to 
more rapid cell-cycling of NSCs/NPCs but does not impair the onset of neurogenesis. The 
increased expression of ID1-3 in DLG2-/- NSCs is consistent with a more rapid cell-cycle, as 
knockout of ID1-3 has been shown to increase cell-cycle length (Niola et al., 2012). ID1-3 
knockout also decreases adhesion to the ventricular surface of embryonic cortex in vivo and 
to laminin and fibronectin in vitro (Niola et al., 2012). In line with this, DLG2-/- NPCs displayed 
increased adhesion to multiple ECM components including fibronectin. 
 
DLG2-/- lines give rise to fewer neurons expressing deep layer marker CTIP2 (BCL11B), 
although bulk mRNA levels recover fully by day 60 (Table S3, Figure 2E). The proportion of 
CTIP2+ cells also significantly recovers over time (Figure S6C-E). Neuronal identity is thought 
to be determined by the internal state of NPCs immediately prior to cell-cycle exit, with 
changes in this state over time leading to the progressive generation of layer VI-II cells (Telley 
et al., 2019). This would suggest that DLG2 loss causes a delay in new-born neurons exhibiting 
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their latent, deep layer identity. This also matches the observed pattern of TBR1 expression. 
TBR1 is expressed by virtually all post-mitotic glutamatergic neurons in vivo but has markedly 
higher expression in early-born neurons (Hevner et al., 2001; Englund et al., 2005) i.e. while 
basal levels of TBR1 are a feature of all new-born neurons, higher levels are associated with 
neurons manifesting deep layer properties. The proportion of TBR1+ neurons does not differ 
between DLG2-/- and wild-type (Figure 2D, G), consistent with no change in the rate of 
neurogenesis. However, total TBR1 mRNA is significantly decreased in DLG2-/- lines at day 30 
(Table S3) indicating a reduced level of expression in individual new-born neurons 
(predominantly deep layer subtypes, as noted earlier). This reduction in TBR1 mRNA recovers 
by day 60 (Table S3), consistent with DLG2 loss delaying the manifestation of deep layer 
identity. The wider changes in gene expression and neuronal physiology seen in DLG2-/- lines 
are also consistent with such a delay. Loss of DLG2 suppresses expression of many genes (85%) 
normally up-regulated between days 20 and 30 in wild-type, coinciding with the onset of 
neurogenesis. Prominent amongst those suppressed are genes contributing to the 
development of cell morphology, connectivity and active properties (Figure 2B, 7A)  W key 
features of neuronal identity  W leading to developing neurons with long, sparsely branched 
primary neurites and immature action potentials (Figure 3, 5). Gene expression recovers by 
day 60, at which point none of the above processes (morphology, connectivity, active 
property development) are over-represented amongst genes dysregulated in DLG2-/- lines 
(data not shown). Morphological deficits persist at least until day 70, although the extent to 
which delayed upregulation of gene expression impacts mature neuronal identity is unclear: 
further work will need to investigate the persistence of deficits in hESC-derived DLG2-/- 
neurons following transplantation into rodent brain. 
 
Genes down-regulated at day 30 in DLG2-/- lines are enriched for rare and common variants 
conferring risk to a wide range of disorders including SZ and ASD (Figure 6E-H), linking DLG2-
dependent neuronal deficits to disease. Consistent with this, multiple independent deletion 
events at the DLG2 locus have been identified in SZ (Kirov et al., 2012) and ASD cases (Ruzzo 
et al., 2019). Previous studies also support a role for SZ and ASD risk factors during 
corticoneurogenesis (Willsey et al., 2013; Polioudakis et al., 2019; Walker et al., 2019). 
Abnormalities in neuronal migration and morphology have been reported in post-mortem 
studies of both disorders (Harrison, 1999; Reiner et al., 2016; Martínez-Cerdeño, 2017) 
although caveats over sample size, reproducibility and confounding via reverse causation 
remain. Here we localise genetic risk to specific gene expression programs regulating these 
phenotypes, supporting their direct involvement in disease pathophysiology. 
 
Disruption of neurogenic transcriptional programs in neurodevelopmental disorders 
The commitment of precursors to a neuronal fate triggers an orchestrated sequence of events 
requiring the timely activation and repression of multiple transcriptional programs. Here we 
identify a cascade of transcriptional programs active during early corticoneurogenesis. While 
much further work is required to validate and refine this model it provides a useful conceptual 
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framework that locates many genetic risk factors in a coherent sequence of cellular events, 
generating insight into the overlapping aetiologies of Mendelian and genetically complex 
neurodevelopmental disorders (Figure 6, 7A). 
 
Major changes in identity require alteration of chromatin structure to reflect cell-type 
differences in gene transcription (Yadav et al., 2018). This is evident in early-transient-/-, in 
which histone- and chromatin-binding genes are highly over-represented (Table S6, Figure 
7A). Known risk genes include chromatin modifier CHD8 (ASD, Neale et al. ? ? ? ? ? ?K ?ZŽĂŬet 
al., 2012; Sanders et al., 2012) and histone methyltransferase SETD1A (NDD & SZ, Singh et al., 
2016). Re-organisation of the transcriptional landscape leads to activation of a second 
expression program (early-stable-/-) which oversees a prolonged phase of cell growth and 
differentiation, accompanied in vivo by radial migration into the appropriate cortical layer 
(Figure 7A). Targets of CHD8 are highly over-represented in early-stable-/- (Figure 4E) 
indicating an important role in the activation of this program. These targets include 
transcription factor TCF4, another major regulator of early-stable-/- genes (Figure 4E) and a 
known interactor of pro-neural genes during differentiation (Flora et al., 2007). Rare 
mutations in TCF4 lead to Pitt-Hopkins syndrome, whose features include ID/NDD (Amiel et 
al., 2007); genome-wide significant (GWS) SZ  association has also been identified at the TCF4 
locus (Ripke et al., 2013,  Pardiñas et al., 2018). Also present are TRIO (SZ, Katrancha et al., 
2017), which promotes reorganization of the actin cytoskeleton during neurite outgrowth 
(Bateman et al., 2000; van Haren et al., 2014), and FMR1 (FMRP) (fragile-X syndrome, Verkerk 
et al., 1991; ASD, Darnell et al., 2011; SZ, Pardiñas et al., 2018). While discussion of FMRP in 
disease has tended to focus on its role in plasticity at mature synapses (Bagni and Zukin, 2019, 
Darnell et al., 2011, Fromer et al., 2014), it is also present in the axons and dendrites of 
developing neurons where it controls growth cone morphology and motility (Antar et al., 
2006). Reflecting this role, targets of FMRP are highly over-represented in early-stable-/- 
(Figure 4E). 
 
TCF4 and FMRP also regulate components of a third program (early-increasing-/-) that shapes 
the emergence of cell-type specific properties: dendrite morphology, synaptic connectivity 
and neuronal activity (Figure 4E, 7A). This program contains transcriptional regulators TBR1 
and BCL11B (CTIP2), markers of deep layer neurons discussed above. TBR1 is enriched for rare 
coding variants in ASD cases (Sanders et al., 2015), while BCL11B lies in a single-gene GWS SZ 
locus (Ripke et al., 2014; Pardiñas et al., 2018). Rare coding variation in genes controlling AP 
propagation has previously been implicated in ASD (De Rubeis et al., 2014); here we find that 
early-increasing-/- genes regulating action potential (AP) firing display stronger evidence for 
SZ association than other elements of this program. These 8 genes encode: voltage-gated 
sodium channels SCN1A-SCN3A (Nav1.1-1.3) and SCN3B (Navɴ ? ); voltage-gated calcium 
channels CACNA1C (Cav1.2), CACNA1I (Cav3.3), CACNA2D1 (CavɲϮི); and hyper-polarization 
activated cyclic-nucleotide-gated channel HCN2.  Na+ influx through Nav1.1-1.3 drives 
membrane depolarisation during AP firing, with K+ efflux driving repolarisation. Membrane 
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hyperpolarisation activates HCN channels, allowing mixed Na+/K+ currents which help restore 
the membrane potential to its resting level (Robinson and Siegelbaum, 2003).  T-type (Cav3.3) 
and L-type (Cav1.2) calcium channels contribute to neuronal firing by initiating rebound 
bursting and controlling calcium-sensitive potassium channels respectively (Simms and 
Zamponi, 2014). Mutations in Nav1.2 (SCN2A) lead to a wide spectrum of epileptic disorders, 
ID and ASD (Wolff et al., 2017). An excess of rare variants in Nav genes has also recently been 
reported for SZ (Rees et al., 2019a). Mutations in Cav1.2 (CACNA1C) lead to Timothy syndrome 
(Splawski et al., 2004) and Brugada syndrome (Watanabe and Minamino, 2016); both 
CACNA1C and CACNA1I are located in single-gene GWS SZ loci (Pardiñas et al., 2018). 
Intriguingly, enhancement of spontaneous calcium transients by Nav activity impedes 
migration and induces premature dendritic branching in developing neurons (Bando et al., 
2016). Cav1.2 (CACNA1C) plays a critical role in spontaneous calcium transient generation in 
the axons and dendrites of developing cortical neurons, with loss of CACNA1C reducing 
neurite growth and a Timothy syndrome gain-of-function mutation impairing radial migration 
(Kamijo et al., 2018). This suggests that, in addition to their role in AP firing, early-increasing-
/- Nav and Cav expression may drive an increase in calcium transients that acts as a cue for 
neurons to end migration and initiate terminal differentiation (dendritic branching and 
synaptogenesis). Deficits in this process could thus alter cell-type specific morphology and 
connectivity, perturbing network formation. Consequently, reduced Nav and Cav gene 
expression (Table S3) may contribute to the reduced neurite branching seen in developing 
DLG2-/- neurons. 
 
One further transcriptional program (late), initiated towards day 60 as developing neurons 
start to become active, upregulates mitochondrial energy production and ion 
transport/homeostatic pathways supporting neuronal signalling (Figure 7A). Peptide 
synthesis and transport are also upregulated, possibly indicating the production of co-
released neuropeptides. Strikingly, this program did not display any evidence for disease-
genetic association. It was however strongly depleted for de novo LoF mutations in NDD cases 
(Figure 6E-F). While there is long-standing interest in the role of mitochondria in disorders 
such as SZ, our data suggest that mitochondrial deficits do not play a major role in the 
developmental aetiology of those disorders studied here. 
 
DLG2 complexes in disease and development 
Disease-relevant genes and physiological processes contributing to mature neuronal function 
also play important (and potentially unexpected e.g. Nav/Cav) roles during development. For 
SZ, disease models with robust genetic support centre upon postsynaptic signalling and the 
regulation of synaptic plasticity by NMDAR/ARC complexes and FMRP (Kirov et al., 2012; 
Fromer et al., 2014; Purcell et al., 2014; Szatkiewicz et al., 2014; Pocklington et al., 2015; 
Genovese et al., 2016). Scaffold protein DLG2 is required for assembly of NMDAR complexes 
at mature synapses (Frank et al., 2016) and we propose a similar mode of action during 
development (Figure 7C). Supporting this, the single invertebrate orthologue of vertebrate 
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genes DLG1-DLG4 (Dlg) is a core component of the Scrib signalling module regulating cell 
polarity, differentiation and migration (Stephens et al., 2018). We propose that DLG2 links 
cell-surface receptors to signal transduction molecules driving the activation of neurogenic 
transcriptional programs. This is normally tightly coupled to cell-cycle exit  W unaffected by 
DLG2 loss (Figure 2) indicating its initiation via independent pathways (Figure 7C). DLG2 
knockout results in stochastic signalling that delays and impairs transcriptional activation, 
disrupting the orchestration of events required for normal development and the precise 
specification of neuronal properties. Proliferation and adhesion deficits observed in DLG2-/- 
NPCs, prior to the onset of neurogenesis, may be driven by similar mechanisms. Aberrant 
chromatin structure in NPCs has been linked to altered neuronal maturation in ASD with 
macrocephaly (Schafer et al., 2019). While common variant analyses did not implicate NPC 
biology in SZ, we do see evidence for rare variant enrichment in genes differentially expressed 
between NSCs and NPCs, indicating a wider role for DLG2 in cell-type transitions relevant to 
disease (unpublished data). 
 
Individuals with SZ, ASD and other disorders carry a highly heterogeneous burden of rare and 
common variants impacting neurogenesis. Whether this results in more or less severe 
disruption than that observed in DLG2-/- cells is not known. Precise timing is crucial during 
brain development, where the correct dendritic morphology, axonal length and electrical 
properties are required for normal cortical and subcortical circuit formation. Consequently, 
even transient perturbation of neurogenesis may have a profound impact on fine-grained 
neuronal wiring, network function and ultimately perception, cognition and behaviour. 
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Figure 1. Study design and initial characterisation of DLG2-/- phenotypes. (A) Study summary. 
DLG2-/- hESCs were generated via the CRISPR/CAS9 system; a sister hESC line that went 
through the gene editing protocol but remained as WT served as a control. hESCs were 
differentiated into cortical excitatory neurons and RNA collected from day 15, 20, 30 and 60 
cultures where the major cell types are neural stem cells (NSCs), neural precursor cells (NPCs), 
new-born and mature neurons respectively. RNA sequencing analysis and subsequent 
experimental validation revealed DLG2-/- phenotypes: increased NSC/NPC proliferation and 
adhesion to extracellular molecules; and decreased expression of deep layer markers, 
reduced morphological complexity, migration and action potential maturity in human cortical 
neurons in vitro. Transcriptional programs active during neurogenesis were identified based 
upon differential gene expression across successive timepoints. SZ common variant risk was 
concentrated in two early programs downregulated in DLG2-/- cells (early-stable-/- and early-
increasing-/-). Loss of function intolerant (LoFi) genes were highly over-represented in all 3 
early expression programs; only LoFi genes in early-stable-/- and -increasing-/- were enriched 
for SZ common risk variants. Early transcriptional programs were enriched for rare LoF 
variants contributing to a wide range of neurodevelopmental/neuropsychiatric disorders; no 
enrichment was seen in rare mutations from unaffected siblings or common risk variants for 
(neurodegenerative disorder) ůǌŚĞŝŵĞƌ ?Ɛ ĚŝƐĞĂƐĞ ? (B) Overview of cortical differentiation 
protocol with approximate timings of key developmental processes and predominant cell 
types present in culture. Asterisks indicate time point selected for RNA sequencing. (C) 
Number of protein coding genes differentially expressed in DLG2-/- cells relative to WT at each 
timepoint (D) Top 5 differentially expressed genes at day 15 of cortical differentiation. Fold 
change is for DLG2-/- expression level relative to WT (E) Adhesion of DLG2-/- and WT cells to 
various ECM protein substrates at day 25 of cortical differentiation.  Both genotype 
(F1,128=38.08; P<0.0001; nt6) and ECM substrate (F7,128=16.20; P<0.0001; nt6) had significant 
effects on adhesion. (F)  Proliferation of DLG2-/- and WT lines maintained as hESCs for 5 days. 
While time (F4,35=1924, P<0.0001; nt3) had a significant effect on hESC proliferation, 
genotype (F1,35=0.3780, P=0.8470; nt3) did not.  (G) Proliferation of DLG2-/- and WT lines from 
days 26 to 36 of cortical differentiation. Both genotype (F1,80=738.5; P<0.0001; nt6) and time 
(F4,80=126.1; P<0.0001; nt6) had significant effects on proliferation and there was a significant 
interaction between these factors (F4,80=59.36; P<0.0001; nt6). Adhesion and proliferation 
data sets (E-G) were analysed by two-way ANOVA with post hoc comparisons using 
Bonferroni correction, comparing to WT controls. Stars above bars represent Bonferroni-
corrected post hoc tests, *P<0.05; **P<0.01; ****P<0.0001 vs. WT control.  All data 
ƉƌĞƐĞŶƚĞĚĂƐŵĞĂŶരA?ര^D ? 
 
.CC-BY-NC-ND 4.0 International licenseauthor/funder. It is made available under a
The copyright holder for this preprint (which was not peer-reviewed) is the. https://doi.org/10.1101/2020.01.10.898676doi: bioRxiv preprint 
 16 
Figure 2. Common risk variants implicate disruption of neurogenesis in schizophrenia. (A) 
Enrichment for common schizophrenia risk variants in genes up- & down-regulated at each 
timepoint (DLG2-/- relative to WT), conditioning on all expressed genes.  Dotted line indicates 
Pcorrected = 0.05 following Bonferroni correction for 8 tests. (B) Gene ontology (GO) terms over-
represented amongst genes down-regulated at day 30 in DLG2-/- lines relative to all expressed 
genes.  (C) NEUN western blot protein bands and histograms of expression normalised to 
GAPDH for DLG2-/- and WT cells at days 30, 40, 50 and 60 of cortical differentiation.  Neither 
genotype (F1,90=0.1852; P=0.6680; nt7) nor time (F3,90=0.5382; P=0.6573; nt7) had significant 
effects on NEUN expression. (D) TBR1 western blot protein bands and histograms of 
expression normalised to GAPDH for DLG2-/- and WT cells at days 30, 40, 50 and 60 of cortical 
differentiation. Neither genotype (F1,95=0.3899; P=0.5338; nt9) nor time (F3,35=0.5052; 
P=0.6793; nt9) had significant effects on TBR1 expression. (E) CTIP2 western blot protein 
bands and histograms of expression normalised to GAPDH for DLG2-/- and WT cells at days 30, 
40, 50 and 60 of cortical differentiation. Both genotype (F1,86=39.89; P<0.0001; nt7) and time 
(F3,86=5.262; P=0.0022; nt7) had significant effects on CTIP2 expression. (F) ICC quantification 
of NEUN expressing nuclei for DLG2-/- and WT cells at 4 time points of cortical differentiation. 
Time (F3,52=7.018, P=0.0005; nt6) had a significant effect on NEUN expression, while 
genotype (F1,52=1.687; P=0.1998; nt6) did not. (G) ICC quantification of TBR1 expressing 
nuclei for DLG2-/- and WT cells at 4 time points of cortical differentiation. Time (F3,58=4.738, 
P=0.0050; nt6) did have a significant effect on TBR1 expression, while genotype (F1,58=1.664; 
P=0.2022; nt6) did not. (H) ICC quantification of CTIP2 expressing nuclei for DLG2-/- and WT 
cells at 4 time points of cortical differentiation. Both genotype (F1,67=101.8; P<0.0001; nt6) 
and time (F3,67=18.93; P<0.0001; nt6) had significant effects on CTIP2 expression. (I) 
Representative ICC images of NEUN, TBR1 and CTIP2 with DAPI nuclear counterstain for 2 
DLG2-/- lines and WT controls at days 30 and 60 of cortical differentiation. Western blotting 
(C-E) and ICC data sets (F-H) were analysed by two-way ANOVA with post hoc comparisons 
using Bonferroni correction, comparing to WT controls. Stars above bars represent 
Bonferroni-corrected post hoc tests, *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001 vs. WT 
ĐŽŶƚƌŽů ?ůůĚĂƚĂƉƌĞƐĞŶƚĞĚĂƐŵĞĂŶരA?ര^D ? 
 
Figure 3. DLG2-/- lines display deficits in neuron morphology & migration. (A) The number of 
primary neurites (projecting from the soma) in DLG2-/- and WT neurons at days 30 and 70 of 
cortical differentiation. Neither genotype (F1,126=1.591; P=0.2095; nt28) nor time 
(F1,126=2.278; P=0.1337; nt28) had significant effects the numbers of primary neurites. (B) 
The number of secondary neurites (projecting from primary neurites) in DLG2-/- and WT 
neurons at days 30 and 70 of cortical differentiation. Genotype (F1,126=18.78, P<0.0001; nt28) 
had a significant effect on number of secondary neurites, while time (F1,126=1.082, P=0.3003; 
nt28) did not. (C) The total neurite length in DLG2-/- and WT neurons at days 30 and 70 of 
cortical differentiation. Both genotype (F1,126=4.568; P=0.0345; nt28) and time (F1,126=26.33; 
P<0.0001; nt28) had significant effects on total neurite length. However, post hoc analysis 
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showed no significant differences at individual timepoints. (D) The soma area of DLG2-/- and 
WT neurons at days 30 and 70 of cortical differentiation. Neither genotype (F1,136=; P=0.9170; 
nt28) nor time (F1,136=1.399; P=0.2390; nt28) had a significant effect on soma area. (E) 
Representative traces showing the morphology of DLG2-/- and WT neurons at days 30 and 70 
of cortical differentiation, scale bars are  ? ? ?ʅŵĂŶĚĂƉƉůǇƚŽďŽƚŚĐĞůůůŝŶĞƐĂƚĂŐŝǀĞŶƚŝŵĞ
point.  (F) The average speed of migration for DLG2-/- and WT neurons over 70 hours, from 
day 40 of cortical differentiation. DLG2-/- neurons showed significantly decreased average 
migration speed compared to WT (t52=6.1175; P<0.0001; n=27). (G) The displacement of 
DLG2-/- and WT neurons at 70 hours migration, from day 40 of cortical differentiation. DLG2-
/- neurons showed significantly decreased displacement compared to WT (t52=3.244; 
P=0.0021; n=27).  (H) Representative traces of neuronal migration from a given origin over 70 
hours, from day 40 of cortical differentiation.  Morphology data sets (A-D) were analysed by 
two-way ANOVA with post hoc comparisons using Bonferroni correction, comparing to WT 
controls. Migration data sets (F-G) were analysed by unpaired two-ƚĂŝůĞĚ ^ƚƵĚĞŶƚ ?Ɛ ƚ-test. 
Stars above bars represent, **P<0.01; ****P<0.0001 vs. WT control (Bonferroni-corrected for 
ŵŽƌƉŚŽůŽŐǇĂŶĂůǇƐĞƐ ) ?ůůĚĂƚĂƉƌĞƐĞŶƚĞĚĂƐŵĞĂŶരA?ര^D ? 
 
Figure 4. DLG2 regulates a cascade of transcriptional programs driving neurogenesis & 
differentiation. (A) Enrichment for common schizophrenia risk variants in genes up- & down-
regulated between each successive pair of timepoints in WT, conditioning on all expressed 
genes.  Dotted line indicates Pcorrected = 0.05 following Bonferroni correction for 6 tests. (B) 
Four discrete transcriptional programs initiated following the onset of neurogenesis were 
identified based upon differential expression between WT timepoints: early-increasing, genes 
significantly upregulated between days 20 and 30 (20-30upWT) and also days 30 and 60 (30-
60upWT); early-stable genes, present in 20-30upWT and 20-60upWT but not 30-60upWT; early-
transient (20-30upWT but not 20-60upWT); and late (30-60upWT but not 20-30upWT).  (C) 
Enrichment for common schizophrenia risk variants in each transcriptional program, further 
split into genes that are down-regulated in DLG2-/- lines at day 30 (e.g. early-stable-/-) and 
those that are not (e.g. early-stableWT only). Tests condition on all expressed genes; Bonferroni 
p-value correction is for 7 tests. (D) SZ GWAS enrichment in programs derived from scRNAseq 
of human foetal cortex (E) Identification of programs over-represented for the targets of key 
regulators (Poverlap) when compared to all expressed genes; all program-regulator enrichments 
identified were taken forward for genetic analysis, testing whether regulator targets were 
more highly enriched for SZ association than other genes in that program (PGWAS).  (F) 
Enrichment for schizophrenia common variant association in GO terms over-represented 
amongst early-increasing-/- genes, conditioning on all expressed and all early-increasing-/- 
genes. 
 
Figure 5. Electrophysiological properties of DLG2-/- neurons (A) Resting membrane potential 
(t27=2.151, P=0.0406) and (B) input resistance (t27=0.3366, P=0.7390) of day 50 WT and DLG2-
/- neurons (n=15 and 14, respectively). (C) Percentages of cells firing action potentials (APs) 
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upon current step injection. (D) Example traces of first overshooting AP and APs evoked by 
current step injection (-60pA to 120pA, increment 20pA, duration 1s). (E) AP height (t16=3.661, 
P=0.0021), (F) AP half-width (t16=4.462, P=0.0004), (G) AP maximum depolarising speed 
(t16=2.463, P=0.0255),  (H) AP maximum repolarising speed (t16=3.728, P=0.0018), (I) spike 
threshold voltage (t16=0.004093, P=0.9968) and (J) rheobase current (t16=0.4061, P=0.6900) 
of day 50 WT and DLG2-/- neurons (n=12 and 6, respectively) are shown. (K) Example of day 
50 neuron being whole-cell patch clamped with fluorescent dye injection. Spontaneous 
excitatory postsynaptic current (sEPSC) examples from day 50 (L) and 60 (M) neurons. Both 
the amplitude and frequency of day 50 and 60 neurons from WT and DLG2-/- neurons were 
comparable (day 50, amplitude: t68=0.6974, P=0.4879, frequency: t66=0.5467, P=0.5865; day 
60 amplitude: t59=1.021, P=0.3114, frequency: t58=0.7671, P=0.4464). (N) Percentage of cells 
displaying sEPSCs. (O) Western blot analysis of DLG4 in synaptosomes of day 65 WT and DLG2-
/- neurons, displaying trend towards increased DLG4 expression in DLG2-/- neurons (t2=2.157, 
P=0.1637). ůůĚĂƚĂƉƌĞƐĞŶƚĞĚĂƐŵĞĂŶരA?ര^D ? 
 
Figure 6. LoF intolerant genes & neurodevelopmental/neuropsychiatric disorder risk 
variants localise to early neurogenic transcriptional programs. (A) Identification of programs 
enriched for LoF intolerant (LoFi) genes (Poverlap) when compared to all expressed genes. (B) 
LoFi genes were partitioned based on their overlap with early-transient-/-, -stable-/- and -
increasing-/- sets. Each segment of the Venn diagram shows the number of genes in each 
ƐƵďƐĞƚĂŶĚƚŚĞƌĞŐƌĞƐƐŝŽŶĐŽĞĨĨŝĐŝĞŶƚ ?ɴ )ĂŶĚ ?ƵŶĐŽƌƌĞĐƚĞĚ )Ɖ-value (P) for SZ common variant 
enrichment, conditioning on all expressed genes. (C) A two-sided Poisson rate ratio test was 
used to identify programs enriched for LoF de novo mutations identified in individuals with SZ 
(Rees et al. in press), comparing each program to all other expressed genes (D) &ŝƌƚŚ ?Ɛ
penalized regression test was used to identify programs with an increased rate of LoF 
singleton mutations identified in SZ cases compared to the rate in controls (Genovese et al., 
2016), conditioning on the rate observed in other expressed genes. (E) A two-sided Poisson 
rate ratio test was used to identify programs enriched for LoF de novo mutations identified in 
individuals with ID/NDD and ASD (Satterstrom et al., 2019) when compared to all other 
expressed genes. Unaffected siblings (SIB) of ASD individuals (Satterstrom et al., 2019) were 
analysed as a control; values for SZ (C) included for comparison. Data points lying above the 
x axis indicate an increased rate (rate ratio > 1), those below indicate a reduced rate (rate 
ratio < 1).  Dotted line indicates Pcorrected = 0.05 following Bonferroni correction for 4 tests 
(each disorder being tested in 4 programs). (F) Rate ratios (genes in program versus all other 
expressed genes) from tests shown in (E). Dotted line shows rate ratio of 1 (i.e. rate of 
mutations in program equals that in all other genes). (G) Programs were tested for 
enrichment in common risk variants contributing to ADHD (Demontis et al., 2019) and BIP 
(Stahl et al., 2019) ĂŶĚůǌŚĞŝŵĞƌ ?ƐĚŝƐĞĂƐĞ ? )(Lambert et al., 2013). Values for SZ (Figure 
4C) included for comparison. (H) ĨĨĞĐƚƐŝǌĞƐ ?ɴ )ĨƌŽŵƚĞƐƚƐƐŚŽǁŶŝŶ ?' ) ? 
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Figure 7. Model of disease pathophysiology in early corticoneurogenesis (A) Summary of 
main GO term enrichments for each transcriptional program (Table S6) and identified 
regulatory interactions between them. (B) Summary of neurodevelopmental 
continuum/gradient model. Disorders shown are: intellectual disability/severe 
neurodevelopmental delay (ID/NDD); autism spectrum disorders (ASD); attention-
deficit/hyperactivity disorder (ADHD); schizophrenia (SZ); and bipolar disorder (BIP) (C) 
Proposed model for DLG2 action in neurodevelopment: External cues transduced by DLG2-
scaffolded complexes activate neurogenic programs underlying cell growth, migration and 
development of active signalling properties; this is normally tightly coupled to cell cycle exit, 
controlled via a DLG2-independent signalling pathway. DLG2 knockout impairs signal 
transduction, disrupting the orchestration of events required for normal development and 
leading to stochastic, imprecise signaling that delays expression of cell-specific properties. 
 
Methods 
hESC culture 
All hESC lines were maintained at 37 C and 5% CO2 in 6 well cell culture plates (Greiner) 
coated with 1% Matrigel hESC-YƵĂůŝĨŝĞĚDĂƚƌŝǆ  ?ŽƌŶŝŶŐ )ƉƌĞƉĂƌĞĚ ŝŶƵůďĞĐĐŽ ?ƐDŽĚŝĨŝĞĚ
Eagle Medium: Nutrient Mixture F-12 (DMEM/F12, Thermo Fisher Scientific). Cells were fed 
daily with Essential 8 medium (E8, Thermo Fisher Scientific) and passaged at 80% confluency 
using Versene solution (Thermo Fisher Scientific) for 1.5 minutes at 37 C followed by manual 
dissociation with a serological pipette. All cells were kept below passage 25 and confirmed as 
negative for mycoplasma infection. 
 
DLG2 Knockout hESC line generation  
Two guide RNAs targeting exon 22 of the human DLG2 gene, covering the first PDZ domain, 
were designed using a web-based tool (crispr.mit.edu) and cloned into two plasmids 
containing D10A nickase mutant Cas9 with GFP (PX461) or Puromycin resistant gene (PX462) 
(Ran et al., 2013). pSpCas9n(BB)-2A-GFP (PX461) and pSpCas9n(BB)-2A-Puro (PX462) was a 
gift from Feng Zhang (For PX461, Addgene plasmid#48140; http://n2t.net/addgene:48140; 
RRID:Addgene_48140; For PX462, Addgene plasmid #48141; http://n2t.net/addgene:48141; 
RRID:Addgene_48141). H7 hESCs (WiCell) were nucleofected using P4 solution and CB150 
programme (Lonza) with 5µg of plasmids, FACS sorted on the following day and plated at a 
low density (~70 cells/cm2) for clonal isolation. 19 clonal populations were established with 6 
WT and 13 mutant lines after targeted sequencing of the exon 22. One WT and two 
homozygous knockout lines were chosen for study. 
 
Genetic validation 
The gRNA pair had zero predicted off-target nickase sites (Figure S2). Even though we did not 
use a wild-type Cas9 nuclease (where only a single gRNA is required to create a double-
stranded break), we further checked genic predicted off-target sites for each individual gRNA 
by PCR and Sanger sequencing (GATC & LGC). Out of 30 sites identified, we randomly selected 
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14 (7 for each gRNA) for validation. No mutations relative to WT were present at any site 
(Table S1). In addition, genotyping on the Illumina PsychArray v1.1 revealed no CNV 
insertions/deletions in either DLG2-/- line relative to WT (Table S2). 
 
Cortical differentiation 
Differentiation to cortical projection neurons (Figure 1A) was achieved using the dual SMAD 
inhibition protocol (Chambers et al., 2009) with modifications (embryoid body to monolayer 
and replacement of KSR medium with N2B27 medium) suggested by (Cambray et al., 2012). 
Prior to differentiation Versene treatment and mechanical dissociation was used to passage 
hESCs at approximately 100,000 cells per well into 12 well cell culture plates (Greiner) coated 
with 1% Matrigel Growth Factor Reduced (GFR) Basement Membrane matrix (Corning) in 
DMEM/F12, cells were maintained in E8 medium at 37 C and 5% CO2 until 90% confluent. At 
day 0 of the differentiation E8 media was replaced with N2B27-RA neuronal differentiation 
media consisting of: 2/3 DMEM/F12, 1/3 Neurobasal (Thermo Fisher Scientific), 1x N-2 
Supplement (Thermo Fisher Scientific), 1x B27 Supplement minus vitamin A (Thermo Fisher 
Scientific), 1x Pen Step Glutamine (Thermo Fisher Scientific) and 50 µM 2-Mercaptoethanol 
(Thermo Fisher Scientific), which was supplemented with 100 nM LDN193189 (Cambridge 
Biosciences) and 10 µM SB431542 (Stratech Scientific) for the first 10 days only (the neural 
induction period). At day 10 cells were passaged at a 2:3 ratio into 12 well cell culture plates 
ĐŽĂƚĞĚǁŝƚŚ ? ?A?Ő ?ŵů,ƵŵĂŶWůĂƐŵĂ&ŝďƌŽŶĞĐƚŝŶ ?DĞƌĐŬ )ŝŶƵůďĞĐĐŽ ?ƐƉŚŽsphate-buffered 
saline (DPBS, Thermo Fisher Scientific), passage was as previously described with the addition 
of a 1 hour incubation with 10 µM Y27632 Dihydrochloride (ROCK inhibitor, Stratech Scientific) 
prior to Versene dissociation. During days 10 to 20 of differentiation cells were maintained in 
N2B27-RA (without LDN193189 or SB431542 supplementation) and passaged at day 20 in a 
1:4 ratio into 24 well cell culture plates (Greiner) sequentially coated with 10 µg/ml poly-d-
lysine hydrobromide (PDL, Sigma) and 15 µg/ml laminin (Sigma) in DPBS.  Vitamin A was 
added to the differentiation media at day 26, standard 1x B27 Supplement (Thermo Fisher 
Scientific) replacing 1x B27 Supplement minus vitamin A, and cells were maintained in the 
resulting N2B27+RA media for the remainder of the differentiation. Cells maintained to day 
40 received no additional passage beyond passage 2 at day 20 while cells kept beyond day 40 
received a third passage at day 30, 1:2 onto PDL-laminin as previously described.  In all cases 
cells maintained past day 30 were fed with N2B27+RA supplemented with 2µg/ml laminin 
once weekly to prevent cell detachment from the culture plates. 
 
Immunocytochemistry 
Cells were fixed in 4% paraformaldehyde (PFA, Sigma) in PBS for 20 minutes at 4 C followed 
by a 1-hour room temperature incubation in blocking solution of 5% donkey serum (Biosera) 
in 0.3% Triton-X-100 (Sigma) PBS (0.3% PBST). Primary antibodies, used at an assay dependent 
concentration, were diluted in blocking solution and incubated with cells overnight at 4 C.  
Following removal of primary antibody solution and 3 PBS washes, cells were incubated in the 
dark for 2 hours at room temperature with appropriate Alexa Fluor secondary antibodies 
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(Thermo Fisher Scientific) diluted 1:500 with blocking solution. After an additional 2 PBS 
washes cells were counterstained with DAPI nucleic acid stain (Thermo Fisher Scientific), 
diluted 1:1000 with PBS, for 5 mins at room temperature and following a final PBS wash 
mounted using Dako Fluorescence Mounting Medium (Agilent) and glass coverslips. Imaging 
was with either the LSM710 confocal microscope (Zeiss) or Cellinsight Cx7 High-Content 
Screening Platform (Thermo Fisher Scientific) with HCS Studio Cell Analysis software (Thermo 
Fisher Scientific) used for quantification. 
 
Western blotting 
Total protein was extracted from dissociated cultured cells by incubating in 1x RIPA buffer 
(New England Biolabs) with added MS-SAFE Protease and Phosphatase Inhibitor (Sigma) for 
30 minutes on ice with regular vortexing, concentration was determined using a DC Protein 
Assay (BioRad) quantified with the CLARIOstar microplate reader (BMG Labtech).  Proteins for 
western blotting were incubated with Bolt LDS sample buffer (Thermo Fisher Scientific) and 
Bolt Sample Reducing Agent (Thermo Fisher Scientific) for 10 minutes at 70 C before loading 
into Bolt 4-12% Bis-Tris Plus gels (Thermo Fisher Scientific).  Gels were run at 120V for 2-3 
hours in Bolt MES SDS Running Buffer (Thermo Fisher Scientific) prior to protein transfer to 
Amersham Protran nitrocellulose blotting membrane (GE Healthcare) using a Mini Trans-Blot 
Cell (BioRad) and Bolt Transfer Buffer (Thermo Fisher Scientific) run at 120V for 1 hour 45 
minutes. Transfer was confirmed by visualising protein bands with 0.1% Ponceau S (Sigma) in 
5% acetic acid (Sigma) followed by repeated H2O washes to remove the stain.  
Following transfer, membranes were incubated in a blocking solution of 5% milk in TBST, 0.1% 
TWEEN 20 (Sigma) in TBS (Formedium), for 1 hour at room temperature.  Primary antibodies, 
used at an assay dependent concentration, were diluted with blocking solution prior to 
incubation with membranes overnight at 4 C.  Following 3 TBST washes, membranes were 
incubated in the dark for 1 hour at room temperature with IRDye secondary antibodies (LI-
COR) diluted 1:15000 with blocking solution. After 3 TBS washes staining was visualised using 
the Odyssey CLx Imaging System (LI-COR). 
 
Synaptosomal preparation 
Synaptic protein was extracted by manually dissociating cultured cells in 1x Syn-PER Reagent 
(Thermo Fisher Scientific) with added MS-SAFE Protease and Phosphatase Inhibitor (Sigma). 
Following low speed centrifugation to pellet cell debris (1,200g, 10 min, 4 C) the supernatant 
was centrifuged at high speed to pellet synaptosomes (15,000g, 20 min, 4 C) which were 
resuspended in fresh Syn-PER Reagent.  Protein concentration was determined using a DC 
Protein Assay (BioRad) quantified with the CLARIOstar microplate reader (BMG Labtech).   
 
Peptide affinity purification 
PDZ domain containing proteins were enriched from total protein extracts by peptide affinity 
purification.  NMDA receptor subunit 2 C-ƚĞƌŵŝŶĂů ƉĞƉƚŝĚĞ  “^/^s ? ǁĂƐ ƐǇŶƚŚĞƐŝƐĞĚ
(Pepceuticals) and fully dissolved in 90% v/v methanol + 1M HEPES pH7 (both Sigma).  
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Dissolved peptide was coupled to Affi-Gel 10 resin (Bio-Rad) that had been washed 3 times in 
methanol, followed by overnight room temperature incubation on a roller mixer.  Unreacted 
NHS groups were subsequently blocked using 1M Tris pH9 (Sigma) with 2 hours room temp 
incubation on a roller mixer.  The peptide bound resin was then washed 3 time with DOC 
buffer (1% w/v sodium deoxycholate; 50mM Tris pH9; 1X MS-SAFE Protease and Phosphatase 
Inhibitor, all Sigma) and stored on ice until required. Total protein was extracted from 
dissociated cultured cells by incubating in DOC buffer for 1 hour on ice with regular vortexing, 
cell debris was pelleted by high speed centrifugation (21,300g, 2 hours, 4 C) and the 
ƐƵƉĞƌŶĂƚĂŶƚĂĚĚĞĚƚŽƚŚĞƉƌĞǀŝŽƵƐůǇƉƌĞƉĂƌĞĚ “^/^s ?ƉĞƉƚŝĚĞďŽƵŶĚƌĞƐŝŶ ?ĨƚĞƌŽǀĞrnight 
4 C incubation on a roller mixer the resin was washed 5 times with ice cold DOC buffer and 
the bound protein eluted by 15-minute 70 C incubation in 5% w/v sodium dodecyl sulphate 
(SDS, Sigma).  The eluted protein was reduced with 10 mM TCEP and alkylated using 20 mM 
Iodoacetamide, trapped and washed on an S-trap micro spin column (ProtiFi, LLC) according 
ƚŽƚŚĞŵĂŶƵĨĂĐƚƵƌĞƌ ?ƐŝŶƐƚƌƵĐƚŝŽŶƐĂŶĚƉƌŽƚĞŝŶĚŝŐĞƐƚĞĚƵƐŝŶŐƚƌǇƉƐŝŶƐĞƋƵĞŶĐĞŐƌĂĚĞ ?WŝĞƌĐĞ )
at 47 C for 1 hour. Eluted peptides were dried in a vacuum concentrator and resuspended in 
0.5% formic acid for MS analysis. Samples were analysed by LC-MS/MS on an Orbitrap Elite 
and data was processed and quantified as described previously (Woodley and Collins, 2019).  
 
CNV analysis 
Following manual dissociation of WT and DLG2 KO hESC into DPBS, genomic DNA was 
extracted using the ISOLATE II Genomic DNA kit (Bioline). Following DNA amplification and 
fragmentation according to the associated Illumina HTS assay protocol samples were 
hybridized to an Infinium PsychArray v1.1 BeadChip (Illumina). The stained bead chip was 
imaged using the iScan System (Illuminia) and Genome Studio v2.0 software (Illumina) 
subsequently used to normalise the raw signal intensity data and perform genotype clustering. 
Final analysis for Copy Number Variation (CNV) was with PennCNV software (Wang et al., 
2007). 
 
RNA sequencing 
WT and DLG2 KO cells were cultured to days 15, 20, 30 and 60 of cortical differentiation as 
described above (See  ‘ŽƌƚŝĐĂůĚŝĨĨĞƌĞŶƚŝĂƚŝŽŶ ? ) ?dŽƚĂůƚƌĂŶƐĐƌŝƉƚŽŵĞZEǁĂƐŝƐŽůĂƚĞĚĨƌŽŵ
triplicate wells for all cell lines at each time point by lysing cells in TRIzol Reagent (Thermo 
Fisher Scientific) followed by purification with the PureLink RNA Mini Kit (Thermo Fisher 
Scientific). RNA quality control (QC) was performed with the RNA 6000 Nano kit analysed 
using the 2100 Bioanalyzer Eukaryote Total RNA Nano assay (Agilent).  cDNA libraries for 
sequencing were produced using the KAPA mRNA HyperPrep Kit for Illumina Platforms (Kapa 
Biosystems) and indexed with KAPA Single-Indexed Adapter Set A + B (Kapa Biosystems). 
Library quantification was by Qubit 1x dsDNA HS Assay kit (Thermo Fisher Scientific) and QC 
by High Sensitivity DNA kit analysed using the 2100 Bioanalyzer High Sensitivity DNA assay 
(Agilent). Sequencing was performed using the HiSeq4000 Sequencing System (Illumina) with 
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libraries split into 2 equimolar pools, each of which was run over 2 flow cell lanes with 75 base 
pair paired end reads and 8 base pair index reads. 
 
All samples were modelled after the long-rna-seq-pipeline used by the PsychENCODE 
Consortium and available at https://www.synapse.org/#!Synapse:syn12026837. Briefly, the 
fastq files from Illumina HiSeq4000 were assessed for quality by using FastQC tool (v0.11.8) 
(Andrews, 2010) and trimmed for adapter sequence and low base call quality (Phred score < 
30 at ends) with cutadapt (v2.3) (Martin, 2011). The mapping of the trimmed reads was done 
using STAR (v2.7.0e) (Dobin et al., 2013) and the BAM files were produced in both genomic 
and transcriptomic coordinates and sorted using samtools (v1.9) (Li et al., 2009). The aligned 
and sorted BAM files were further assessed for quality using Picard tools (v2.20.2) (Broad 
Institue, 2019).  This revealed a high level of duplicate reads in day 30 KO2 samples (~72% 
compared to an average of 23% for other samples). These samples were removed prior to 
further analyses.  GRCh38.p13 was used as the reference genome and the comprehensive 
gene annotations on the primary assembly from Gencode (release 32) used as gene 
annotation. Gene and transcript-level quantifications were calculated using RSEM (v1.3.1) (Li 
and Dewey, 2011). Both STAR and RSEM executions were performed using the psychENCODE 
parameters.  
 
RSEM gene and isoform level estimated counts were imported using the tximport package 
(v1.12.3) (Soneson et al., 2015). Protein coding genes expressed (cpm>=1) in at least 1/3 of 
the samples were taken forward for differential analyses of genes, transcripts and exons. 
Differential gene expression analysis was performed using the DESeq2 package (v1.24.0) (Love 
et al., 2014) and differentially expressed genes were considered significant if their p value 
after Bonferroni correction was < 0.05. Differential exon usage was analysed using the DEXSeq 
pipeline (Anders et al., 2012). Briefly, the GENCODE annotation .gtf file was translated into a 
.gff file with collapsed exon counting bins by using the dexseq_prepare_annotation.py script. 
Mapped reads overlapping each of the exon counting bins were then counted using the 
python_count.py script and the HTSEQ software (0.11.2) (Anders et al., 2015). Finally, 
differential exon usage was evaluated using DEXSeq (v1.30) (Anders et al., 2012) and 
significant differences identified using an FDR threshold of 0.05. All the differential analyses 
were performed by using R (v3.6.1). 
 
When analysing differential gene expression in DLG2-/- relative to WT, samples from KO1 and 
KO2 lines were combined i.e. for each timepoint a single differential gene expression analysis 
was performed, comparing expression in KO1 & KO2 samples against wild-type. To assess the 
impact of sample dropout for day 30, we compared differential expression results when 
performed separately for each line (i.e.  KO1 v WT and KO2 v WT) at day 20: the timepoint 
closest to day 30 and with a comparable number of differentially expressed genes (Figure 1B). 
The overlap in expressed genes accounted for 99% of the genes expressed in each line and the 
overlap in differentially expressed genes (those with Bonferroni P < 0.05) was 85%. Fold 
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change and differential expression p-values ǁĞƌĞŚŝŐŚůǇĐŽƌƌĞůĂƚĞĚ ?^ƉĞĂƌŵĂŶ ?Ɛხ = 0.95 and 
0.85 respectively) between lines.  GO term enrichment analyses were also extremely robust. 
GO terms significantly enriched (Bonferroni P < 0.05) in up- and down-regulated genes 
(denoted up and down respectively) displayed a high degree of overlap between the 2 lines; 
overlapping terms accounted for 68% KO1up, 94% KO2up, 90% KO1down and 90% KO2down 
enriched GO terms. GO term p-ǀĂůƵĞƐǁĞƌĞƐƚƌŽŶŐůǇĐŽƌƌĞůĂƚĞĚ ?^ƉĞĂƌŵĂŶ ?Ɛხup = 0.85, ხdown 
= 0.87), as were GO term odds ratios  W used in our iterative refinement procedure to identify 
semi-ŝŶĚĞƉĞŶĚĞŶƚƚĞƌŵƐ ?^ƉĞĂƌŵĂŶ ?Ɛხup = 0.92, ხdown = 0.95). Differential expression data 
from each line is thus highly comparable and the potential impact of sample dropout is limited. 
 
Transcriptional programs 
Genes were partitioned based upon their WT expression profiles as follows. Differentially 
expressed genes (Bonferroni P < 0.05) were first identified between pairs of timepoints 
(analysing WT data only): genes up-regulated in day 30 relative to day 20 (20-30upWT); genes 
up-regulated in day 60 relative to day 30 (30-60upWT); and genes up-regulated in day 60 relative 
to day 20 (20-60upWT). Early-transient, early-stable, early-increasing and late programs were 
then defined based upon the intersections of these gene-sets as shown in Figure 4B. 
 
Single-cell RNA sequencing data 
Single-cell RNA-Seq gene expression data from (Nowakowski et al., 2017) were downloaded 
from bit.ly/cortexSingleCell. The principal cell-types present at each timepoint in culture 
(Figure 1B) were mapped onto sub-types identified in vivo as follows: 
 
day 20 NPCs: "RG-div1", "RG-div2", "oRG", "tRG", "vRG", "IPC-div1", "IPC-div2", "IPC-nEN1", 
"IPC-nEN2", and "IPC-nEN3" clusters 
day 30 neurons (new-born): "nEN-early1", "nEN-early2", and "nEN-late" clusters 
day 60 neurons: "EN-PFC1","EN-PFC2","EN-PFC3","EN-V1-1","EN-V1-2", and "EN-V1-3" 
clusters 
 
Differential expression analysis was performed on protein coding genes using Seurat (v 
3.1.1) (Butler et al., 2018) with a Wilcoxon Rank Sum test and without any internal filtering. 
Analysis was restricted to cells with at least 5% of their genes expressed (tpm>0) and genes 
expressed in at least 5% of cells in the smallest group of the comparison. Differentially 
expressed genes (Bonferroni P < 0.05) were identified between pairs of timepoints and used 
to define transcriptional programs as above. 
 
Gene set construction 
GO 
The Gene Ontology (GO) ontology tree was downloaded from OBO: 
http://purl.obolibrary.org/obo/go/go-basic.obo 
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Ontology trees were constructed separately for Molecular Function, Biological Process and 
ĞůůƵůĂƌŽŵƉŽŶĞŶƚƵƐŝŶŐ ‘ŝƐ YĂ ?ĂŶĚ ‘ƉĂƌƚ YŽĨ ?ƌĞůĂƚŝŽŶƐŚŝƉƐ ?'KĂŶŶŽƚĂƚŝŽŶƐǁĞƌĞĚŽǁŶůŽĂĚĞĚ
from NCBI: 
ftp://ftp.ncbi.nlm.nih.gov/gene/DATA/gene2go.gz 
Annotations containing the negative qualifier NOT were removed, as were all annotations with 
evidence codes IEA, NAS and RCA. Annotations were further restricted to protein-coding 
genes.  Genes corresponding to each annotation term were then annotated with all parents 
of that term, identified using the appropriate ontology tree. Finally, terms containing between 
20 and 2000 genes were extracted for analysis. 
 
Regulator targets 
Predicted TBR1 and BCL11B targets (Wang et al., 2018): Transcription factor-target gene 
interactions identified by elastic net regression were downloaded from the PsychEncode 
resource website (http://resource.psychencode.org/#Derived) and predicted targets for TBR1 
and BCL11B extracted (interaction file: INT-11_ElasticNet_Filtered_Cutoff_0.1_GRN_1.csv).  
Gene symbols were mapped to NCBI/Entrez ids using data from the NCBI gene_info file. 
 
TCF4 targets (Forrest et al., 2018): identifiers were updated using the gene_history file from 
NCBI. 
 
FMRP targets (Darnell et al., 2011): NCBI/Entrez mouse gene identifiers were updated using 
the gene_history file from NCBI. Genes were then mapped from mouse to human using 
Homologene, restricting to protein-coding genes with a 1-1 mapping. 
 
Direct CHD8 mid-foetal promoter targets (Cotney et al., 2015): symbols (NCBI gene_info file) 
and locations (NCBI Build37.3) were used to map genes to NCBI/Entrez gene ids. Note: using 
(Sugathan et al., 2014) rather than (Cotney et al., 2015) to define direct CHD8 targets did not 
alter the observed pattern of overlap with transcriptional programs (Figure 4)(data not shown). 
 
Indirect CHD8 targets (Sugathan et al., 2014): Ensembl ids were updated (Ensembl 
stable_id_event file) then mapped to current NCBI/Entrez ids using Ensembl and NCBI id cross-
reference files. Taking genes with altered expression on CHD8 shRNA knockdown, we removed 
those identified as direct CHD8 targets in NPCs (Sugathan et al., 2014) or as CHD8 mid-foetal 
promoter targets (Cotney et al., 2015). Using a stricter definition of genes with altered 
expression on CHD8 shRNA knockdown than that taken by (Sugathan et al., 2014) - genes with 
a Bonferroni corrected differential expression P < 0.05, rather than genes with a nominal P < 
0.05 - did not alter the pattern of overlap with transcriptional programs (data not shown). 
 
Functional over-representation test (gene set overlap) 
dŚĞĚĞŐƌĞĞŽĨŽǀĞƌůĂƉďĞƚǁĞĞŶ ƉĂŝƌƐŽĨŐĞŶĞƐĞƚƐǁĂƐĞǀĂůƵĂƚĞĚƵƐŝŶŐ&ŝƐŚĞƌ ?ƐǆĂĐƚ ƚĞƐƚ ?
where the background set consisted of all genes expressed in either WT or DLG2-/- lines 
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(allWT+KO). This was used for GO terms, the analysis of regulator targets (Figure 4E) and the 
overlap between LoFi genes and transcriptional programs (Figure 6A). In order to identify a 
semi-independent subset of functionally enriched annotations from the output of functional 
enrichment tests (Figure 4F, Table S5-6), we used an iterative refinement procedure. Briefly, 
we selected the gene set with the largest enrichment odds ratio; removed all genes in this set 
from all other enriched annotations; re-tested these reduced gene-sets for enrichment in 
30down-/- genes; then discarded gene-ƐĞƚƐǁŝƚŚWA?  ? ? ? ?  ?ĂĨƚĞƌŽŶĨĞƌƌŽŶŝ-correction for the 
number of sets tested in that iteration).  This process was repeated (with gene-sets being 
cumulatively depleted of genes at each iteration) until there were no remaining sets with a 
corrected P < 0.05. 
 
Common variant association 
All common variant gene-set enrichment analyses were performed using the competitive 
gene-set enrichment test implemented in MAGMA version 1.07, conditioning on allWT+KO using 
the condition-residualize function. To test whether GO terms (Figure 4F, Table S7) or regulator 
targets (Figure 4E) enriched in a specific program captured more or less of the SZ association 
in these programs than expected, a two-sided enrichment test was performed on term/target 
genes within the program, conditioning on allWT+KO and on all genes in the program. All other 
GWAS enrichment tests were one-sided. To test whether common variant enrichment 
differed between two gene-sets, we ƚŽŽŬƚŚĞƌĞŐƌĞƐƐŝŽŶĐŽĞĨĨŝĐŝĞŶƚɴĂŶĚŝƚƐƐƚĂŶĚĂƌĚĞƌƌŽƌ
^ ?ɴ )ĨŽƌĞĂĐŚŐĞŶĞ-set from the MAGMA output file and compared z = d/SE(d) to a standard 
ŶŽƌŵĂůĚŝƐƚƌŝďƵƚŝŽŶ ?ǁŚĞƌĞĚA?ɴ1  W ɴ2 ĂŶĚ^ ?Ě )A?A? ?^ ?ɴ1)2 A ^ ?ɴ2)2]. Gene-level association 
statistics for schizophrenia were taken from (Pardiñas et al., 2018); those for ADHD (Demontis 
et al., 2019), bipolar disorder (Stahl et al., 2019) and AD (Lambert et al., 2013) were calculated 
using the MAGMA multi model, with a fixed 20,000 permutations for each gene.  
 
Rare variant association 
The de novo LoF mutations for SZ analysed here are described in (Rees et al., 2019b). De novo 
LoF mutations for NDD, ASD and unaffected siblings of individuals with ASD were taken from 
(Satterstrom et al., 2019): these were re-annotated using VEP (McLaren et al., 2016) and 
mutations mapping to > 2 genes (once readthrough annotations had been discarded) were 
removed from the analysis. A two-sided Poisson rate ratio test was used to evaluate whether 
the enrichment of de novo LoF mutations in specific gene-sets was significantly greater than 
that observed for all other expressed genes. The expected rate of de novo LoF mutations in a 
set of genes was estimated using individual gene mutation rates (Ware et al., 2015). &ŝƌƚŚ ?Ɛ
penalized regression was used to test gene-sets for an increased rate of LoF singleton 
mutations identified in cases compared to the rate of LoF singleton mutations identified in 
controls (case-control data from Genovese et al., 2016). The set of all expressed genes 
(allWT+KO ) was included as a covariate and all tests were two-sided. 
 
Migration assay 
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Cells were cultured and differentiated to cortical projection neurons as previously described. 
Neuronal migration was measured during a 70-hour period from day 40 by transferring cell 
culture plates to the IncuCyte Live Cell Analysis System (Sartorius). Cells were maintained at 
37 C and 5% CO2 with 20X magnification phase contrast images taken of whole wells in every 
2 hours for the analysis period. The StackReg plugin (Thévenaz, 2011) for ImageJ was used to 
fully align the resulting stacks of time lapse-images after which the cartesian coordinates of 
individual neuronal soma were recorded over the course of the experiment, enabling the 
distance and speed of neuronal migration to be calculated. Data sets (Figure 3F, G) were 
analysed by unpaired two-ƚĂŝůĞĚ^ƚƵĚĞŶƚ ?Ɛ t-test. 
 
Adhesion assay 
Cells were differentiated towards cortical projection neurons as previously described and 
dissociated to single cells at day 25 by 15-minute incubation with Accutase solution (Sigma).  
100,000 cells per well were plated onto various ECM substrates (Collagen I, Collagen II, 
Collagen IV, Fibronectin, Laminin, Tenascin, Vitronectin) and the ECM540 Cell Adhesion Array 
Kit (EMD Millipore) was used to assess cell adhesion.  The degree of adhesion to each ECM 
substrate was quantified following cell staining by absorbance at 560 nm, using the 
CLARIOstar microplate reader (BMG Labtech). Data sets (Figure 1E) were analysed by two-
way ANOVA with post hoc comparisons using Bonferroni correction, comparing to WT 
controls. 
 
Morphology analysis 
Cells were differentiated to cortical projection neurons essentially as described and neuronal 
morphology assessed at days 30 and 70.  To generate low density cultures for analysis, cells 
were passaged at either day 25 or 50 using 15-minute Accutase solution (Sigma) dissociation 
followed by plating at 100,000 cells per well on 24 well culture plates.  72 hours prior to 
morphology assessment cells were transfected with 500ng pmaxGFP (Lonza) per well using 
Lipofectaime 3000 Reagent (Thermo Fisher Scientific) and Opti-MEM Reduced Serum Media 
(Thermo Fisher Scientific) for the preparation of DNA-lipid complexes.  At days 30 or 70, cells 
were fixed in 4% paraformaldehyde (PFA, Sigma) in PBS for 20 minutes at 4 C before 
mounting with Dako Fluorescence Mounting Medium (Agilent) and glass coverslips.  Random 
fields were imaged using a DMI6000B Inverted microscope (Leica) and the morphology of GFP 
expressing cells with a clear neuronal phenotype quantified using the Neurolucida 360 (MBF 
Bioscience) neuron tracing and analysis software package. Data sets (Figure 3A-D) were 
analysed by two-way ANOVA with post hoc comparisons using Bonferroni correction, 
comparing to WT controls. 
 
Proliferation assay 
hESCs were either maintained in E8 medium or differentiated towards cortical projection 
neurons as required for the assay.  At the time point of interest single-cell suspensions were 
produced by 15-minute Accutase solution (Sigma) incubation and cells plated at a density of 
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300,000 cells per well into 5 wells of a 24-well.  Cells were maintained in appropriate media 
and allowed to proliferate from this point for either a 5-10 day period, with the total number 
of cells present within a well quantified colorimetrically at 1 or 2 day intervals. Using 
components of the ECM540 Cell Adhesion Array Kit (EMD Millipore) all cells within a well were 
stained using Cell Stain Solution (EMD Millipore) and following repeated H2O washes to 
remove excess, cells were lysed to release bound stain using Extraction Buffer (EMD Millipore).  
The absorbance at 560 nm of the Extraction Buffer, being relative to the total number of cells 
within the stained well, was quantified using a CLARIOstar microplate reader (BMG Labtech). 
Data sets (Figure 1F, G) were analysed by two-way ANOVA with post hoc comparisons using 
Bonferroni correction, comparing to WT controls. 
 
Electrophysiology 
Whole cell patch clamp electrophysiology was performed on cells cultured on 13mm round 
coverslips. On day 20 of hESC differentiation, 250,000 human neural precursor cells from WT 
and KO hESCs were dissociated and plated on each PDL-coated coverslip in 30µl diluted (20x) 
matrigel (Corning) together with 20,000 rat primary glial cells. Postnatal day 7 -10 old 
Sprague-Dawley rats (Charles River) bred in-house were sacrificed via cervical dislocation and 
cortex was quickly dissected. Tissues were dissociated using 2mg/ml papain and plated in 
DMEM supplemented with 10% Foetal bovine serum and 1% 
penicillin/streptomycin/Amphotericin B and 1x Glutamax (all Thermo Fisher Scientific). 
Microglia and oligodendrocyte precursor cells were removed by shaking at 500 rpm for 24 
hours at 37 C.  All animal procedures were performed in accordance with Cardiff University's 
animal care committee's regulations and the European Directive 2010/63/EU on the 
protection of animals used for scientific purposes. Plated cells were fed with BrainPhys 
medium (Stem cell Technologies) supplemented with 1x B27 (Thermo Fisher Scientific), 
10ng/ml BDNF (Cambridge Bioscience) and 200µM ascorbic acid (Sigma). To stop the 
proliferation of cells, 1x CultureOne (Thermo Fisher Scientific) was supplemented from day 
21. For postsynaptic current experiment, coverslips were transferred to a recording chamber 
(RC-26G, Warner Instruments) and perfused with HEPES Buffered Saline (HBS) (119 mM NaCl; 
5 mM KCl; 25 mM HEPES; 33 mM glucose; 2mM CaCl2; 2mM MgCl2; 1µM glycine; 100µM 
picrotoxin; pH 7.4), at a flow rate of 2-3 ml per minute. Recordings were made using pipettes 
pulled from borosilicate glass capillaries (1.5 mm OD, 0.86 mm ID, Harvard Apparatus), and 
experiments were performed at room temperature (~20 C). mEPSC recordings were made 
using recording electrodes filled with a Cs-based intracellular filling solution (130 mM 
CsMeSO4; 8 mM NaCl; 4 mM Mg-ATP; 0.3 mM Na-GTP, 0.5 mM EGTA; 10 mM HEPES; 6 mM 
QX-314; with pH 7.3 and osmolarity ~295 mOsm). Cells were voltage clamped at -60 mV using 
a Multiclamp 700B amplifier (Axon Instruments). Continuous current acquisition, series 
resistance and input resistance were monitored and analysed online and offline using the 
WinLTP software (Anderson and Collingridge, 2007; http://www.winltp.com). Only cells with 
ƐĞƌŝĞƐƌĞƐŝƐƚĂŶĐĞAM ? ?DɏǁŝƚŚĂĐŚĂŶŐĞŝŶƐĞƌŝĞƐƌĞƐŝƐƚĂŶĐĞAM ? ?A?ĨƌŽŵƚŚĞƐƚĂƌƚǁĞƌĞŝŶĐůƵĚĞĚ
in this study. Data were analysed by importing Axon Binary Files into Clampfit (version 10.6; 
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Molecular Devices). A threshold function of >12 pA was used to identify mEPSC events, which 
were then subject to manual confirmation. Results were outputted to SigmaPlot (version 12.5, 
Systat Software), where analysis of peak amplitude and frequency of events was performed. 
The current clamp was used to record resting membrane potential (RMP) and action 
potentials (AP). Data were sampled at 20kHz with a 3 kHz Bessel filter with MultiClamp 700B 
amplifier.  Coverslips were transferred into the recording chamber maintained at RT (20-21 C) 
on the stage of an Olympus BX61W (Olympus) differential interference contrast (DIC) 
microscope and perfused at 2.5ml/min with the external solution composed of 135mM NaCl, 
3mM KCl, 1.2mM MgCl2, 1.25mM CaCl2, 15mM D-glucose, 5mM HEPES (all from Sigma), and 
pH was titrated to 7.4 by NaOH. The internal solution used to fill the patch pipettes was 
composed of 117mM KCl, 10mM NaCl, 11mM HEPES, 2mM Na2-ATP, 2mM Na-GTP, 1.2mM 
Na2-phosphocreatine, 2mM MgCl2, 1mM CaCl2 and 11mM EGTA (all from Sigma), and pH was 
titrated to 7.3 by NaOH. The resistance of a patch pipette was 3 W ? Dɏ ĂŶĚ ƚŚĞ ƐĞƌŝĞƐ
resistance component was fully compensated using the bridge balance function of the 
instrument. The resting membrane potential (RMP) of cells was recorded immediately after 
breaking into the cells in gap free mode. A systematic current injection protocol (duration, 1 
s; increment, 20 pA; from -60pA to 120pA) was applied to the neurons held at -60mV to evoke 
APs. Input resistance (Rin) was calculated by Rin=(Vi-Vm)/I, where Vi is the potential recorded 
from -10pA current step. The AP properties are measured by the first over shooting AP. 
Further analysis for action potential characterization was carried out by Clampfit 10.7 
software (Molecular Devices). 
 
Statistical analysis and data presentation 
Unless specifically stated in each methodology section, GraphPad Prism (version 8.3.0) was 
used to test the statistical significance of the data and to produce the graphs. Stars above 
bars in each graph represents Bonferroni-corrected post hoc tests, *P<0.05; **P<0.01; 
****P<0.0001 vs. WT control.  In panels for phenotypic assays in Figures 1 & 2, n indicates 
the number of replicates used (from at least two independent differentiations). All data 
ƉƌĞƐĞŶƚĞĚ ĂƐ ŵĞĂŶരA?ര^D ?Dotted lines in the p value graphs (Figure 2A, 4A, 6E and 6G) 
indicate Pcorrected = 0.05 following Bonferroni correction. 
 
Bonferroni test correction 
GO term analyses were corrected for the ~4,200 terms tested. 
Figure 2A  W corrected for 8 tests (up & down regulated x 4 timepoints) 
Figure 4A  W corrected for 6 tests (up & down regulated x 3 pairs of timepoints) 
Figure 4C  W corrected for 7 tests (7 gene expression programs) 
Figure 4D  W corrected for 4 tests (4 gene expression programs) 
Figure 4E (Poverlap)  W corrected for 21 tests (7 regulator target sets x 3 programs) 
Figure 4E (PGWAS)    W corrected for 10 tests (10 over-represented sets taken forward for genetic 
analysis) 
Figure 4F  W corrected for 16 tests (16 semi-independent over-represented GO terms) 
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Table S7 W corrected for 13 tests (13 semi-independent over-represented GO terms) 
Figure 6A  W corrected for 4 tests (4 programs) 
Figure 6B  W uncorrected (secondary, exploratory analysis) 
Figure 6C  W corrected for 4 tests (4 programs) 
Figure 6D  W corrected for 4 tests (4 programs) 
Figure 6E  W each disorder (& SIB) corrected for 4 tests (4 programs) 
Figure 6G  W each disorder corrected for 4 tests (4 programs) 
 
Supplemental Information 
Figure S1. Generation of DLG2-/- human embryonic stem cell lines, Related to Figure 1 
Figure S2. Quality of two gRNAs used in the study, Related to Figure 1 
Figure S3. Validation of DLG2-/- human embryonic stem cells, Related to Figure 1 
Figure S4. Quality control of DLG2-/- human embryonic stem cells, Related to Figure 1 
Figure S5. Characterisation of cortical differentiation of DLG2-/- and WT hESCs, Related to 
Figure 1 
Figure S6. The phenotype of two DLG2 knockout cell lines, Related to Figure 1 & 2 
Table S1. CRISPR/Cas9 off-target validation, Related to Figure 1, S1 & S2 
Table S2. DLG2 and SCRIB unique peptides (LC-MS/MS of day 30 samples), Related to Figure 
1 & S3 
Table S3. Differential gene expression (KO v WT and successive WT timepoints), Related to 
Figure 1 & 4 
Table S4. GO over-representation analysis (KO V WT days 15 and 20, up- and down-regulated 
genes), Related to Figure 1 
Table S5. GO over-representation analysis (KO V WT day 30 down-regulated genes), Related 
to Figure 2 & 3 
Table S6. GO over-representation analysis (neurogenic transcriptional programs), Related to 
Figure 4 & 7 
Table S7. Schizophrenia GWAS enrichment (GO terms over-represented in early-stable-/-), 
Related to Figure 4 
 
References 
Amiel, J., Rio, M., de Pontual, L., Redon, R., Malan, V., Boddaert, N., Plouin, P., Carter, N.P., 
Lyonnet, S., Munnich, A., et al. (2007). Mutations in TCF4, encoding a class I basic helix-loop-
helix transcription factor, are responsible for Pitt-Hopkins syndrome, a severe epileptic 
encephalopathy associated with autonomic dysfunction. Am. J. Hum. Genet. 80, 988 W993. 
Anders, S., Reyes, A., and Huber, W. (2012). Detecting differential usage of exons from RNA-
seq data. Genome Res. 22, 2008 W2017. 
Anders, S., Pyl, P.T., and Huber, W. (2015). HTSeq--a Python framework to work with high-
throughput sequencing data. Bioinformatics 31, 166 W169. 
Anderson, W.W., and Collingridge, G.L. (2007). Capabilities of the WinLTP data acquisition 
program extending beyond basic LTP experimental functions. J. Neurosci. Methods 162, 346 W
.CC-BY-NC-ND 4.0 International licenseauthor/funder. It is made available under a
The copyright holder for this preprint (which was not peer-reviewed) is the. https://doi.org/10.1101/2020.01.10.898676doi: bioRxiv preprint 
 31 
356. 
Andrews, S. (2010). FastQC: A Quality Control tool for High Throughput Sequence Data.  
Available online at: https://www.bioinformatics.babraham.ac.uk/projects/fastqc/. 
Antar, L.N., Li, C., Zhang, H., Carroll, R.C., and Bassell, G.J. (2006). Local functions for FMRP in 
axon growth cone motility and activity-dependent regulation of filopodia and spine synapses. 
Mol. Cell. Neurosci. 32, 37 W48. 
Anttila, V., Bulik-Sullivan, B., Finucane, H.K., Walters, R.K., Bras, J., Duncan, L., Escott-Price, V., 
Falcone, G.J., Gormley, P., Malik, R., et al. (2018). Analysis of shared heritability in common 
disorders of the brain. Science 360, eaap8757. 
Bagni, C., and Zukin, R.S. (2019). A Synaptic Perspective of Fragile X Syndrome and Autism 
Spectrum Disorders. Neuron 101, 1070 W1088. 
Bando, Y., Irie, K., Shimomura, T., Umeshima, H., Kushida, Y., Kengaku, M., Fujiyoshi, Y., Hirano, 
T., and Tagawa, Y. (2016). Control of Spontaneous Ca 2+ Transients Is Critical for Neuronal 
Maturation in the Developing Neocortex. Cereb. Cortex 26, 106 W117. 
Bateman, J., Shu, H., and Van Vactor, D. (2000). The Guanine Nucleotide Exchange Factor Trio 
Mediates Axonal Development in the Drosophila Embryo. Neuron 26, 93 W106. 
von Bohlen und Halbach, O. (2007). Immunohistological markers for staging neurogenesis in 
adult hippocampus. Cell Tissue Res. 329, 409 W420. 
Broad Institue (2019). Picard Tools. Available online at: 
https://broadinstitute.github.Io/picard/. 
Butler, A., Hoffman, P., Smibert, P., Papalexi, E., and Satija, R. (2018). Integrating single-cell 
transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. 
36, 411 W420. 
Cambray, S., Arber, C., Little, G., Dougalis, A.G., De Paola, V., Ungless, M.A., Li, M., and 
Rodríguez, T.A. (2012). Activin induces cortical interneuron identity and differentiation in 
embryonic stem cell-derived telencephalic neural precursors. Nat. Commun. 3, 841. 
Chambers, S.M., Fasano, C.A., Papapetrou, E.P., Tomishima, M., Sadelain, M., and Studer, L. 
(2009). Highly Efficient neural conversion of ES/iPS by SMAD Inhibition. Nat. Biotechnol. 27, 
275 W280. 
Clifton, N.E., Hannon, E., Harwood, J.C., Di Florio, A., Thomas, K.L., Holmans, P.A., Walters, 
: ?d ?Z ? ?K ?ŽŶŽǀĂŶ ?D ? ? ?KǁĞŶ ?D ?: ? ?WŽĐŬůŝŶŐƚŽŶ ? ?: ? ?ĞƚĂů ?  ?  ? ? ? ) ?ǇŶĂŵŝĐĞǆƉƌĞƐƐŝŽŶŽĨ
genes associated with schizophrenia and bipolar disorder across development. Transl. 
Psychiatry 9, 74. 
Cotney, J., Muhle, R.A., Sanders, S.J., Liu, L., Willsey, A.J., Niu, W., Liu, W., Klei, L., Lei, J., Yin, 
J., et al. (2015). The autism-associated chromatin modifier CHD8 regulates other autism risk 
genes during human neurodevelopment. Nat. Commun. 6, 6404. 
Cox, J., and Mann, M. (2008). MaxQuant enables high peptide identification rates, 
individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat. 
Biotechnol. 26, 1367 W1372. 
Craddock, N., and Owen, M.J. (2010). The Kraepelinian dichotomy - going, going... but still not 
gone. Br. J. Psychiatry 196, 92 W95. 
.CC-BY-NC-ND 4.0 International licenseauthor/funder. It is made available under a
The copyright holder for this preprint (which was not peer-reviewed) is the. https://doi.org/10.1101/2020.01.10.898676doi: bioRxiv preprint 
 32 
Darnell, J.C., Van Driesche, S.J., Zhang, C., Hung, K.Y.S., Mele, A., Fraser, C.E., Stone, E.F., Chen, 
C., Fak, J.J., Chi, S.W., et al. (2011). FMRP stalls ribosomal translocation on mRNAs linked to 
synaptic function and autism. Cell 146, 247 W261. 
Demontis, D., Walters, R.K., Martin, J., Mattheisen, M., Als, T.D., Agerbo, E., Baldursson, G., 
Belliveau, R., Bybjerg-Grauholm, J., Bækvad-Hansen, M., et al. (2019). Discovery of the first 
genome-wide significant risk loci for attention deficit/hyperactivity disorder. Nat. Genet. 51, 
63 W75. 
Dobin, A., Davis, C.A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., 
and Gingeras, T.R. (2013). STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15 W
21. 
Englund, C., Fink, A., Lau, C., Pham, D., Daza, R.A.M., Bulfone, A., Kowalczyk, T., and Hevner, 
R.F. (2005). Pax6, Tbr2, and Tbr1 are expressed sequentially by radial glia, intermediate 
progenitor cells, and postmitotic neurons in developing neocortex. J. Neurosci. 25, 247 W251. 
Flora, A., Garcia, J.J., Thaller, C., and Zoghbi, H.Y. (2007). The E-protein Tcf4 interacts with 
Math1 to regulate differentiation of a specific subset of neuronal progenitors. Proc. Natl. Acad. 
Sci. U. S. A. 104, 15382 W15387. 
Forrest, M.P., Hill, M.J., Kavanagh, D.H., Tansey, K.E., Waite, A.J., and Blake, D.J. (2018). The 
Psychiatric Risk Gene Transcription Factor 4 (TCF4) Regulates Neurodevelopmental Pathways 
Associated With Schizophrenia, Autism, and Intellectual Disability. Schizophr. Bull. 44, 1100 W
1110. 
&ƌĂŶŬ ?Z ? ?t ? ?<ŽŵŝǇĂŵĂ ?E ?, ? ?ZǇĂŶ ?d ?: ? ?ŚƵ ?& ? ?K ?Ğůů ?d ?: ? ?ĂŶĚ'ƌĂŶƚ ?^  ?' ?E ? ? ? ? ? ? ) ?ED
receptors are selectively partitioned into complexes and supercomplexes during synapse 
maturation. Nat. Commun. 7, 11264. 
Fromer, M., Pocklington, A.J., Kavanagh, D.H., Williams, H.J., Dwyer, S., Gormley, P., 
Georgieva, L., Rees, E., Palta, P., Ruderfer, D.M., et al. (2014). De novo mutations in 
schizophrenia implicate synaptic networks. Nature 506, 179 W184. 
Genovese, G., Fromer, M., Stahl, E.A., Ruderfer, D.M., Chambert, K., Landén, M., Moran, J.L., 
Purcell, S.M., Sklar, P., Sullivan, P.F., et al. (2016). Increased burden of ultra-rare protein-
altering variants among 4,877 individuals with schizophrenia. Nat. Neurosci. 19, 1433 W1441. 
Girirajan, S., Rosenfeld, J.A., Coe, B.P., Parikh, S., Friedman, N., Goldstein, A., Filipink, R.A., 
McConnell, J.S., Angle, B., Meschino, W.S., et al. (2012). Phenotypic heterogeneity of genomic 
disorders and rare copy-number variants. N. Engl. J. Med. 367, 1321 W1331. 
Harrison, P.J. (1997). Schizophrenia: a disorder of neurodevelopment? Curr. Opin. Neurobiol. 
7, 285 W289. 
Harrison, P.J. (1999). The neuropathology of schizophrenia A critical review of the data and 
their interpretation. Brain 122, 593 W624. 
Hevner, R.F., Shi, L., Justice, N., Hsueh, Y.-P., Sheng, M., Smiga, S., Bulfone, A., Goffinet, A.M., 
Campagnoni, A.T., and Rubenstein, J.L.. (2001). Tbr1 Regulates Differentiation of the Preplate 
and Layer 6. Neuron 29, 353 W366. 
Hill, M.J., and Bray, N.J. (2012). Evidence That Schizophrenia Risk Variation in the ZNF804A 
Gene Exerts Its Effects During Fetal Brain Development. Am. J. Psychiatry 169, 1301 W1308. 
.CC-BY-NC-ND 4.0 International licenseauthor/funder. It is made available under a
The copyright holder for this preprint (which was not peer-reviewed) is the. https://doi.org/10.1101/2020.01.10.898676doi: bioRxiv preprint 
 33 
Husi, H., and Grant, S.G.N. (2001). Isolation of 2000-kDa complexes of N-methyl-D-aspartate 
receptor and postsynaptic density 95 from mouse brain. J. Neurochem. 77, 281 W291. 
Jung, S., Park, R.-H., Kim, S., Jeon, Y.-J., Ham, D.-S., Jung, M.-Y., Kim, S.-S., Lee, Y.-D., Park, C.-
H., and Suh-Kim, H. (2010). Id Proteins Facilitate Self-Renewal and Proliferation of Neural 
Stem Cells. Stem Cells Dev. 19, 831 W841. 
Kamijo, S., Ishii, Y., Horigane, S.-I., Suzuki, K., Ohkura, M., Nakai, J., Fujii, H., Takemoto-Kimura, 
S., and Bito, H. (2018). A Critical Neurodevelopmental Role for L-Type Voltage-Gated Calcium 
Channels in Neurite Extension and Radial Migration. J. Neurosci. 38, 5551 W5566. 
Kang, H.J., Kawasawa, Y.I., Cheng, F., Zhu, Y., Xu, X., Li, M., Sousa, A.M.M., Pletikos, M., Meyer, 
K.A., Sedmak, G., et al. (2011). Spatio-temporal transcriptome of the human brain. Nature 
478, 483 W489. 
Katrancha, S.M., Wu, Y., Zhu, M., Eipper, B.A., Koleske, A.J., and Mains, R.E. (2017). 
Neurodevelopmental disease-associated de novo mutations and rare sequence variants 
affect TRIO GDP/GTP exchange factor activity. Hum. Mol. Genet. 26, 4728 W4740. 
Katrancha, S.M., Shaw, J.E., Zhao, A.Y., Myers, S.A., Cocco, A.R., Jeng, A.T., Zhu, M., Pittenger, 
C., Greer, C.A., Carr, S.A., et al. (2019). Trio Haploinsufficiency Causes Neurodevelopmental 
Disease-Associated Deficits. Cell Rep. 26, 2805-2817.e9. 
Kirov, G., Pocklington, A.J., Holmans, P., Ivanov, D., Ikeda, M., Ruderfer, D., Moran, J., 
Chambert, K., Toncheva, D., Georgieva, L., et al. (2012). De novo CNV analysis implicates 
specific abnormalities of postsynaptic signalling complexes in the pathogenesis of 
schizophrenia. Mol. Psychiatry 17, 142 W153. 
Krichevsky, A.M., and Kosik, K.S. (2001). Neuronal RNA Granules: A Link between RNA 
Localization and Stimulation-Dependent Translation. Neuron 32, 683 W696. 
Lambert, J.C., Ibrahim-Verbaas, C.A., Harold, D., Naj, A.C., Sims, R., Bellenguez, C., DeStafano, 
A.L., Bis, J.C., Beecham, G.W., Grenier-Boley, B., et al. (2013). Meta-analysis of 74,046 
ŝŶĚŝǀŝĚƵĂůƐŝĚĞŶƚŝĨŝĞƐ ? ?ŶĞǁƐƵƐĐĞƉƚŝďŝůŝƚǇůŽĐŝĨŽƌůǌŚĞŝŵĞƌ ?ƐĚŝƐĞĂƐĞ ?EĂƚ ?'ĞŶĞƚ ?45, 1452 W
1458. 
van de Leemput, J., Boles, N.C., Kiehl, T.R., Corneo, B., Lederman, P., Menon, V., Lee, C., 
Martinez, R.A., Levi, B.P., Thompson, C.L., et al. (2014). CORTECON: A temporal transcriptome 
analysis of in vitro human cerebral cortex development from human embryonic stem cells. 
Neuron 83, 51 W68. 
de Leeuw, C.A., Mooij, J.M., Heskes, T., and Posthuma, D. (2015). MAGMA: generalized gene-
set analysis of GWAS data. PLoS Comput. Biol. 11, e1004219. 
Li, B., and Dewey, C.N. (2011). RSEM: accurate transcript quantification from RNA-Seq data 
with or without a reference genome. BMC Bioinformatics 12, 323. 
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., 
Durbin, R., and 1000 Genome Project Data Processing Subgroup, 1000 Genome Project Data 
Processing (2009). The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 
2078 W2079. 
Long, K.R., Newland, B., Florio, M., Kalebic, N., Langen, B., Kolterer, A., Wimberger, P., and 
Huttner, W.B. (2018). Extracellular Matrix Components HAPLN1, Lumican, and Collagen I 
.CC-BY-NC-ND 4.0 International licenseauthor/funder. It is made available under a
The copyright holder for this preprint (which was not peer-reviewed) is the. https://doi.org/10.1101/2020.01.10.898676doi: bioRxiv preprint 
 34 
Cause Hyaluronic Acid-Dependent Folding of the Developing Human Neocortex. Neuron 99, 
702-719.e6. 
Love, M.I., Huber, W., and Anders, S. (2014). Moderated estimation of fold change and  
dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550. 
Martin, M. (2011). Cutadapt removes adapter sequences from high-throughput sequencing 
reads. EMBnet.Journal 17, 10 W12. 
Martínez-Cerdeño, V. (2017). Dendrite and spine modifications in autism and related 
neurodevelopmental disorders in patients and animal models. Dev. Neurobiol. 77, 393 W404. 
McLaren, W., Gil, L., Hunt, S.E., Riat, H.S., Ritchie, G.R.S., Thormann, A., Flicek, P., and 
Cunningham, F. (2016). The Ensembl Variant Effect Predictor. Genome Biol. 17, 122. 
Murray, R.M., and Lewis, S.W. (1987). Is schizophrenia a neurodevelopmental disorder? Br. 
Med. J. (Clin. Res. Ed). 295, 681 W682. 
EĞĂůĞ ? ?D ? ?<ŽƵ ?z ? ?>ŝƵ ?> ? ?DĂ ?ayan, A., Samocha, K.E., Sabo, A., Lin, C.-F., Stevens, C., Wang, 
L.-S., Makarov, V., et al. (2012). Patterns and rates of exonic de novo mutations in autism 
spectrum disorders. Nature 485, 242 W245. 
Niola, F., Zhao, X., Singh, D., Castano, A., Sullivan, R., Lauria, M., Nam, H., Zhuang, Y., Benezra, 
R., Di Bernardo, D., et al. (2012). Id proteins synchronize stemness and anchorage to the niche 
of neural stem cells. Nat. Cell Biol. 14, 477 W487. 
Nowakowski, T.J., Bhaduri, A., Pollen, A.A., Alvarado, B., Mostajo-Radji, M.A., Di Lullo, E., 
Haeussler, M., Sandoval-Espinosa, C., Liu, S.J., Velmeshev, D., et al. (2017). Spatiotemporal 
gene expression trajectories reveal developmental hierarchies of the human cortex. Science 
358, 1318 W1323. 
K ?ZŽĂŬ ? ?: ? ?sŝǀĞƐ ?> ? ?'irirajan, S., Karakoc, E., Krumm, N., Coe, B.P., Levy, R., Ko, A., Lee, C., 
Smith, J.D., et al. (2012). Sporadic autism exomes reveal a highly interconnected protein 
network of de novo mutations. Nature 485, 246 W250. 
KǁĞŶ ? D ?: ? ? ĂŶĚ K ?ŽŶŽǀĂŶ ? D ? ?  ? ? ? ? ? ) ? Schizophrenia and the neurodevelopmental 
continuum:evidence from genomics. World Psychiatry 16, 227 W235. 
KǁĞŶ ? D ?: ? ? K ?ŽŶŽǀĂŶ ? D ? ? ? dŚĂƉĂƌ ?  ? ? ĂŶĚ ƌĂĚĚŽĐŬ ? E ? ? ? ? ? ? ) ? EĞƵƌŽĚĞǀĞůŽƉŵĞŶƚĂů
hypothesis of schizophrenia. Br. J. Psychiatry 198, 173 W175. 
Pardiñas, A.F., Holmans, P., Pocklington, A.J., Escott-Price, V., Ripke, S., Carrera, N., Legge, S.E., 
Bishop, S., Cameron, D., Hamshere, M.L., et al. (2018). Common schizophrenia alleles are 
enriched in mutation-intolerant genes and in regions under strong background selection. Nat. 
Genet. 50, 381 W389. 
Pocklington, A.J., Rees, E., Walters, J.T.R., Han, J., Kavanagh, D.H., Chambert, K.D., Holmans, 
P., Moran, J.L., McCarroll, S.A., Kirov, G., et al. (2015). Novel Findings from CNVs Implicate 
Inhibitory and Excitatory Signaling Complexes in Schizophrenia. Neuron 86, 1203 W1214. 
Polioudakis, D., de la Torre-Ubieta, L., Langerman, J., Elkins, A.G., Shi, X., Stein, J.L., Vuong, 
C.K., Nichterwitz, S., Gevorgian, M., Opland, C.K., et al. (2019). A Single-Cell Transcriptomic 
Atlas of Human Neocortical Development during Mid-gestation. Neuron 103, 785-801.e8. 
WƵƌĐĞůů ?^  ?D ? ?tƌĂǇ ?E ?Z ? ?^ ƚŽŶĞ ?: ?> ? ?sŝƐƐĐŚĞƌ ?W ?D ? ?K ?ŽŶŽǀĂŶ ?D ? ? ?^ ƵůůŝǀĂŶ ?W ?& ? ?ĂŶĚ^ ŬůĂƌ ?
P. (2009). Common polygenic variation contributes to risk of schizophrenia and bipolar 
.CC-BY-NC-ND 4.0 International licenseauthor/funder. It is made available under a
The copyright holder for this preprint (which was not peer-reviewed) is the. https://doi.org/10.1101/2020.01.10.898676doi: bioRxiv preprint 
 35 
disorder. Nature 460, 748 W752. 
WƵƌĐĞůů ?^ ?D ? ?DŽƌĂŶ ?: ?> ? ?&ƌŽŵĞƌ ?D ? ?ZƵĚĞƌĨĞƌ ? ? ?^ŽůŽǀŝ ĨĨ E  ZŽƵƐƐŽƐ ?W ? ?K ?ƵƐŚůĂŝŶĞ ? ? ?
Chambert, K., Bergen, S.E., Kähler, A., et al. (2014). A polygenic burden of rare disruptive 
mutations in schizophrenia. Nature 506, 185 W190. 
Ran, F.A., Hsu, P.D., Wright, J., Agarwala, V., Scott, D.A., and Zhang, F. (2013). Genome 
engineering using the CRISPR-Cas9 system. Nat. Protoc. 8, 2281 W2308. 
Rees, E., Walters, J.T.R., Georgieva, L., Isles, A.R., Chambert, K.D., Richards, A.L., Mahoney-
Davies, G., Legge, S.E., Moran, J.L., McCarroll, S.A., et al. (2014). Analysis of copy number 
variations at 15 schizophrenia-associated loci. Br. J. Psychiatry 204, 108 W114. 
Rees, E., Carrera, N., Morgan, J., Hambridge, K., Escott-Price, V., Pocklington, A.J., Richards, 
A.L., Pardiñas, A.F., GROUP Investigators, G., McDonald, C., et al. (2019a). Targeted 
Sequencing of 10,198 Samples Confirms Abnormalities in Neuronal Activity and Implicates 
Voltage-Gated Sodium Channels in Schizophrenia Pathogenesis. Biol. Psychiatry 85, 554 W562. 
Rees, E., Han, J., Morgan, J., Carrera, N., Escott-Price, V., Pocklington, A.J., Duffield, M., Hall, 
L., Legge, S.E., Pardiñas, A.F., et al. (2019b). De novo mutations identified by exome 
sequencing implicate rare missense variants in SLC6A1 in schizophrenia. Nat. Neurosci. In 
press. 
Reiner, O., Karzbrun, E., Kshirsagar, A., and Kaibuchi, K. (2016). Regulation of neuronal 
migration, an emerging topic in autism spectrum disorders. J. Neurochem. 136, 440 W456. 
ZŝƉŬĞ ?^ ? ?K ?ƵƐŚůĂŝŶĞ ? ? ?Chambert, K., Moran, J.L., Kähler, A.K., Akterin, S., Bergen, S.E., 
Collins, A.L., Crowley, J.J., Fromer, M., et al. (2013). Genome-wide association analysis 
identifies 13 new risk loci for schizophrenia. Nat. Genet. 45, 1150 W1159. 
Ripke, S., Neale, B.M., Corvin, A., Walters, J.T., Farh, K.-H., Holmans, P.A., Lee, P., Bulik-Sullivan, 
B., Collier, D.A., Huang, H., et al. (2014). Biological insights from 108 schizophrenia-associated 
genetic loci. Nature 511, 421 W427. 
Robinson, R.B., and Siegelbaum, S.A. (2003). Hyperpolarization-Activated Cation Currents: 
From Molecules to Physiological Function. Annu. Rev. Physiol. 65, 453 W480. 
De Rubeis, S., He, X., Goldberg, A.P., Poultney, C.S., Samocha, K., Cicek, A.E., Kou, Y., Liu, L., 
Fromer, M., Walker, S., et al. (2014). Synaptic, transcriptional and chromatin genes disrupted 
in autism. Nature 515, 209 W215. 
Ruzzo, E.K., Pérez-Cano, L., Jung, J.-Y., Wang, L., Kashef-Haghighi, D., Hartl, C., Singh, C., Xu, J., 
Hoekstra, J.N., Leventhal, O., et al. (2019). Inherited and De Novo Genetic Risk for Autism 
Impacts Shared Networks. Cell 178, 850-866.e26. 
Sanders, S.J., Murtha, M.T., Gupta, A.R., Murdoch, J.D., Raubeson, M.J., Willsey, A.J., Ercan-
Sencicek, A.G., DiLullo, N.M., Parikshak, N.N., Stein, J.L., et al. (2012). De novo mutations 
revealed by whole-exome sequencing are strongly associated with autism. Nature 485, 237 W
241. 
Sanders, S.J., He, X., Willsey, A.J., Ercan-Sencicek, A.G., Samocha, K.E., Cicek, A.E., Murtha, 
M.T., Bal, V.H., Bishop, S.L., Dong, S., et al. (2015). Insights into Autism Spectrum Disorder 
Genomic Architecture and Biology from 71 Risk Loci. Neuron 87, 1215 W1233. 
Satterstrom, F.K., Kosmicki, J.A., Wang, J., Breen, M.S., Rubeis, S. De, An, J.-Y., Peng, M., Collins, 
.CC-BY-NC-ND 4.0 International licenseauthor/funder. It is made available under a
The copyright holder for this preprint (which was not peer-reviewed) is the. https://doi.org/10.1101/2020.01.10.898676doi: bioRxiv preprint 
 36 
R., Grove, J., Klei, L., et al. (2019). Large-scale exome sequencing study implicates both 
developmental and functional changes in the neurobiology of autism. BioRxiv 484113. 
Schafer, S.T., Paquola, A.C.M., Stern, S., Gosselin, D., Ku, M., Pena, M., Kuret, T.J.M., Liyanage, 
M., Mansour, A.A.F., Jaeger, B.N., et al. (2019). Pathological priming causes developmental 
gene network heterochronicity in autistic subject-derived neurons. Nat. Neurosci. 22, 243 W
255. 
Schneider, C.A., Rasband, W.S., and Eliceiri, K.W. (2012). NIH Image to ImageJ: 25 years of 
Image Analysis. Nat. Methods 9, 671 W675. 
Sebat, J., Levy, D.L., and McCarthy, S.E. (2009). Rare structural variants in schizophrenia: one 
disorder, multiple mutations; one mutation, multiple disorders. Trends Genet. 25, 528 W535. 
Simms, B.A., and Zamponi, G.W. (2014). Neuronal Voltage-Gated Calcium Channels: Structure, 
Function, and Dysfunction. Neuron 82, 24 W45. 
Singh, T., Kurki, M.I., Curtis, D., Purcell, S.M., Crooks, L., McRae, J., Suvisaari, J., Chheda, H., 
Blackwood, D., Breen, G., et al. (2016). Rare loss-of-function variants in SETD1A are associated 
with schizophrenia and developmental disorders. Nat. Neurosci. 19, 571 W577. 
Soneson, C., Love, M.I., and Robinson, M.D. (2015). Differential analyses for RNA-seq: 
transcript-level estimates improve gene-level inferences. F1000Research 4, 1521. 
Splawski, I., Timothy, K.W., Sharpe, L.M., Decher, N., Kumar, P., Bloise, R., Napolitano, C., 
Schwartz, P.J., Joseph, R.M., Condouris, K., et al. (2004). CaV1.2 Calcium Channel Dysfunction 
Causes a Multisystem Disorder Including Arrhythmia and Autism. Cell 119, 19 W31. 
Stahl, E.A., Breen, G., Forstner, A.J., McQuillin, A., Ripke, S., Trubetskoy, V., Mattheisen, M., 
Wang, Y., Coleman, J.R.I., Gaspar, H.A., et al. (2019). Genome-wide association study 
identifies 30 loci associated with bipolar disorder. Nat. Genet. 51, 793 W803. 
Stephens, R., Lim, K., Portela, M., Humbert, P.O., and Richardson, H.E. (2018). The Scribble 
Cell Polarity Module in the Regulation of Cell Signaling in Tissue Development and 
Tumorigenesis. J. Mol. Biol. 430, 3585 W3612. 
Sugathan, A., Biagioli, M., Golzio, C., Erdin, S., Blumenthal, I., Manavalan, P., Ragavendran, A., 
Brand, H., Lucente, D., Miles, J., et al. (2014). CHD8 regulates neurodevelopmental pathways 
associated with autism spectrum disorder in neural progenitors. Proc. Natl. Acad. Sci. U. S. A. 
111, E4468-77. 
^ǌĂƚŬŝĞǁŝĐǌ ?: ?W ? ?K ?ƵƐŚůĂŝŶĞ ? ? ?ŚĞŶ ?' ? ?ŚĂŵďĞƌƚ ?< ? ?DŽƌĂŶ ?: ?> ? ?EĞĂůĞ ? ?D ? ?&ƌŽŵĞƌ ?D ? ?
Ruderfer, D., Akterin, S., Bergen, S.E., et al. (2014). Copy number variation in schizophrenia in 
Sweden. Mol. Psychiatry 19, 762 W773. 
Telley, L., Agirman, G., Prados, J., Amberg, N., Fièvre, S., Oberst, P., Bartolini, G., Vitali, I., 
Cadilhac, C., Hippenmeyer, S., et al. (2019). Temporal patterning of apical progenitors and 
their daughter neurons in the developing neocortex. Science 364, eaav2522. 
Thévenaz, P. (2011). StackReg - An ImageJ plugin for the recursive alignment of a stack of 
images. 
van Haren, J., Boudeau, J., Schmidt, S., Basu, S., Liu, Z., Lammers, D., Demmers, J., Benhari, J., 
Grosveld, F., Debant, A., et al. (2014). Dynamic Microtubules Catalyze Formation of Navigator-
TRIO Complexes to Regulate Neurite Extension. Curr. Biol. 24, 1778 W1785. 
.CC-BY-NC-ND 4.0 International licenseauthor/funder. It is made available under a
The copyright holder for this preprint (which was not peer-reviewed) is the. https://doi.org/10.1101/2020.01.10.898676doi: bioRxiv preprint 
 37 
Verkerk, A.J.M.H., Pieretti, M., Sutcliffe, J.S., Fu, Y.-H., Kuhl, D.P.A., Pizzuti, A., Reiner, O., 
Richards, S., Victoria, M.F., Zhang, F., et al. (1991). Identification of a gene (FMR-1) containing 
a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile 
X syndrome. Cell 65, 905 W914. 
Walker, R.L., Ramaswami, G., Hartl, C., Mancuso, N., Gandal, M.J., de la Torre-Ubieta, L., 
Pasaniuc, B., Stein, J.L., and Geschwind, D.H. (2019). Genetic Control of Expression and 
Splicing in Developing Human Brain Informs Disease Mechanisms. Cell 179, 750-771.e22. 
Wang, D., Liu, S., Warrell, J., Won, H., Shi, X., Navarro, F.C.P., Clarke, D., Gu, M., Emani, P., 
Yang, Y.T., et al. (2018). Comprehensive functional genomic resource and integrative model 
for the human brain. Science 362, eaat8464. 
Wang, K., Li, M., Hadley, D., Liu, R., Glessner, J., Grant, S.F.A., Hakonarson, H., and Bucan, M. 
(2007). PennCNV: an integrated hidden Markov model designed for high-resolution copy 
number variation detection in whole-genome SNP genotyping data. Genome Res. 17, 1665 W
1674. 
Ware, J.S., Samocha, K.E., Homsy, J., and Daly, M.J. (2015). Interpreting de novo Variation in 
Human Disease Using denovolyzeR. Curr. Protoc. Hum. Genet. 87, 7.25.1-7.25.15. 
Watanabe, H., and Minamino, T. (2016). Genetics of Brugada syndrome. J. Hum. Genet. 61, 
57 W60. 
Weinberger, D.R. (1987). Implications of Normal Brain Development for the Pathogenesis of 
Schizophrenia. Arch. Gen. Psychiatry 44, 660 W669. 
Williams, N.M., Zaharieva, I., Martin, A., Langley, K., Mantripragada, K., Fossdal, R., Stefansson, 
H., Stefansson, K., Magnusson, P., Gudmundsson, O.O., et al. (2010). Rare chromosomal 
deletions and duplications in attention-deficit hyperactivity disorder: a genome-wide analysis. 
Lancet (London, England) 376, 1401 W1408. 
Willsey, A.J., Sanders, S.J., Li, M., Dong, S., Tebbenkamp, A.T., Muhle, R.A., Reilly, S.K., Lin, L., 
Fertuzinhos, S., Miller, J.A., et al. (2013). Coexpression networks implicate human midfetal 
deep cortical projection neurons in the pathogenesis of autism. Cell 155, 997 W1007. 
Wolff, M., Johannesen, K.M., Hedrich, U.B.S., Masnada, S., Rubboli, G., Gardella, E., Lesca, G., 
Ville, D., Milh, M., Villard, L., et al. (2017). Genetic and phenotypic heterogeneity suggest 
therapeutic implications in SCN2A-related disorders. Brain 140, 1316 W1336. 
tŽŽĚůĞǇ ?< ?d ? ?ĂŶĚŽůůŝŶƐ ?D ?K ? ? ? ? ? ? ) ?^ ?ĂĐǇůĂƚĞĚ'ŽůŐĂ ?ďƐ ĂďŝůŝƐĞƐ,, ?ĂƚƚŚĞƉůĂƐŵĂ
membrane to regulate cell adhesion. EMBO Rep. 20, e47472. 
Yadav, T., Quivy, J.P., and Almouzni, G. (2018). Chromatin plasticity: A versatile landscape that 
underlies cell fate and identity. Science (80-. ). 361, 1332 W1336. 
 
.CC-BY-NC-ND 4.0 International licenseauthor/funder. It is made available under a
The copyright holder for this preprint (which was not peer-reviewed) is the. https://doi.org/10.1101/2020.01.10.898676doi: bioRxiv preprint 
BA
C D
NCBI Symbol
log
2
 fold 
change
SE P P
corrected
3397 ID1 3.52 0.11 5.73x10-216 7.57x10-212
3399 ID3 2.67 0.093 4.85x10-183 6.41x10-179
3398 ID2 2.29 0.083 7.88x10-168 1.04x10-163
151449 GDF7 3.70 0.15 3.49x10-135 4.61x10-131
1277 COL1A1 1.43 0.059 5.12x10-130 6.77x10-126
up
down
Day 15 Day 20 Day 30 Day 60
0
500
1000
1500
2000
2500
3000
3500
4000
4500
N
 g
e
n
e
 (
p
ro
te
in
 c
o
d
in
g
)
E F G
0 10 205 15 25 30 35 40 45 50 55 60
Matrigel Fibronectin Poly-D-lysine + Laminin
N2B27 without RA N2B27 with RA
LDN + SB
Neural induction Neurulation Neurogenesis Synaptogenesis
hESCs / NSCs NSCs NPCs Immature neurons
+ NPCs
Mature neurons
+ Immature neurons & NPCs
* * * *
Days
Substrate
Media
Factors
Processes
Cell Types
RNAseq
C
ol
lla
ge
n 
I
C
ol
lla
ge
n 
II
C
ol
la
ge
n 
IV
Fi
br
on
ec
tin
La
m
in
in
Te
na
sc
in
Vi
tro
ne
ct
in
N
eg
at
iv
e 
(B
S
A
)
0.0
0.5
1.0
1.5
2.0
2.5
O
D
 5
6
0
n
m
*
**
**
1 2 3 4 5
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
O
D
 5
6
0
n
m
DLG2+/+ hESCs
DLG2-/- hESCs
DLG2+/+ NPCs
DLG2-/- NPCs
Days maintained as hESCs
Day 28 Day 30 Day 32 Day 34 Day 36
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
5.0
5.5
6.0
6.5
O
D
 5
6
0
 n
m
*
****
****
****
****
Days of cortical differentiation
Figure 1
Rare mutation Transcriptional control
Mid-foetal expression
DLG2
DLG2-/- & isogenic WT hESCs 
Cortical excitatory neuron differentiation
RNA seq
DEG, GO analysis, experimental validation
NSC
D15
NPC
D20
Newborn neuron
D30
NSC/NPC stages
Schizophrenia
SNV/indel
Enriched for SZ 
common risk variants
Neuronal stages
Disease genetics of neurogenic 
transcriptional programs 
Mature neuron
D60
CRISPR/CAS9
Morpholgical complexity
Deep layer markers
Migration
Action potential maturity
Proliferation
ECM adhesion
- de novo LoF
- LoF singleton
GWAS association (in vitro & in vivo)
enriched not enriched
Loss of function (LoF) intolerant genes
- LoFi GWAS association
- LoFi overlap
Cross disorder
GWAS
- AD (control)
- ADHD
- BIP
- SIB (control)
De novo LoF
- NDD
- ASD
G
e
n
e
 e
x
p
re
s
s
io
n
D20 D30 D60
Early-increasing-/-
Late
Early-stable-/-
Early-transient-/-
-/- 
down-regulated 
in DLG2-/- (D30)
DLG2+/+ NPCs
DLG2-/- NPCs
.CC-BY-NC-ND 4.0 International licenseauthor/funder. It is made available under a
The copyright holder for this preprint (which was not peer-reviewed) is the. https://doi.org/10.1101/2020.01.10.898676doi: bioRxiv preprint 
A 
GO term Noverlap OR Poverlap P
corrected
membrane depolarization
504 1.86 5.71x10-23 2.36x10-19
synapse assembly
149 3.18 4.76x10
-20 1.97x10-16
regulation of small GTPase mediated signal transduction
164 2.72 7.44x10
-18 3.07x10-14
axon
96 3.93 7.99x10
-17 3.30x10-13
peptidyl serine phosphorylation
157 2.60 4.48x10-16 1.85x10-12
protein import into nucleus
80 4.30 1.77x10-15 7.29x10-12
neuron migration
82 3.53 3.62x10-13 1.49x10-9
positive regulation of neuron projection development
104 2.39 6.89x10-10 2.85x10-6
calcium ion transport into cytosol
23 10.77 1.67x10-8 6.90x10-5
regulation of adherens junction organization
38 4.05 9.34x10-8 0.00039
synaptic membrane
30 5.02 1.92x10-7 0.00079
protein phosphorylated amino acid binding
27 5.27 4.91x10-7 0.0020
DNA binding transcription factor activity RNA polymerase II specific
20 7.80 1.06x10-6 0.0044
neurotransmitter receptor complex 26 5.08 1.15x10-6 0.0047
microtubule end
22 6.44 1.22x10-6 0.0050neuron recognition
32 3.95 1.31x10-6 0.0054
ubiquitin like protein ligase activity
62 2.39 1.60x10-6 0.0066
positive regulation of axonogenesis
37 3.34 2.04x10-6 0.0084
calcium ion regulated exocytosis
80 2.09 1.93x10-6 0.0080
neuron projection morphogenesis
23 5.38 2.93x10-6 0.012
regulation of cell morphogenesis
28 4.10 4.03x10-6 0.017
modification dependent protein binding
27 3.95 8.66x10-6 0.036
regulation of synapse assembly
27 3.95 8.66x10-6 0.036
B 
overlap
Figure 2
WT (DLG2+/+) KO1 (DLG2-/-) KO2 (DLG2-/-)
TBR1 DAPI
I 
 CTIP2 DAPI
WT (DLG2+/+) KO1 (DLG2-/-) KO2 (DLG2-/-)
Day 30 cortical differentiation Day 60 cortical differentiation
NEUN DAPI
100µm
F 
Day 30 Day 40 Day 50 Day 60
0
10
20
30
40
50
60
70
80
N
E
U
N
+
 n
u
c
le
i (
%
)
Day 30 Day 40 Day 50 Day 60
0
10
20
30
C
T
IP
2
+
 n
u
c
le
i (
%
)
*******
****
H 
Day 60
G 
Day 30 Day 40 Day 50
0
10
20
30
40
T
B
R
1
+
 n
u
c
le
i (
%
)
DLG2+/+
DLG2-/-
Day 30 Day 40 Day 50 Day 60
0.0
0.5
1.0
1.5
2.0
N
E
U
N
/G
A
P
D
H
Day 30 Day 40 Day 50 Day 60
0.0
0.5
1.0
1.5
T
B
R
1
/G
A
P
D
H
Day 30 Day 40 Day 50 Day 60
0
2
4
6
8
C
T
IP
2
/G
A
P
D
H
NEUN
GAPDH
+/+ +/+ +/+ +/+-/- -/- -/- -/-
Day 30 Day 40 Day 50 Day 60C 
TBR1
GAPDH
+/+ +/+ +/+ +/+-/- -/- -/- -/-
Day 30 Day 40 Day 50 Day 60D 
CTIP2
GAPDH
+/+ +/+ +/+ +/+-/- -/- -/- -/-
Day 30 Day 40 Day 50 Day 60E 
****
***
*
Day 15 Day 20 Day 30 Day 60
0
1
2
3
4
5
6
7
8
9
-l
o
g
1
0
(P
G
W
A
S
)
up
down
(DLG2-/- vs WT DEG)
Bonferroni P=0.05
.CC-BY-NC-ND 4.0 International licenseauthor/funder. It is made available under a
The copyright holder for this preprint (which was not peer-reviewed) is the. https://doi.org/10.1101/2020.01.10.898676doi: bioRxiv preprint 
01
2
3
N
u
m
b
e
r 
p
ri
m
a
ry
  
n
e
u
ri
te
s
Day 30 Day 70
0.00
0.02
0.04
0.06
0.08
0.10
A
ve
ra
g
e
 m
ig
ra
tio
n
 s
p
e
e
d
 (
µ
m
/m
in
)
****
0
20
40
60
80
100
D
is
p
la
c
e
m
e
n
t 
a
t 
7
0
 h
o
u
rs
 
m
ig
ra
ti
o
n
 (
µ
m
)
**
DLG2+/+ DLG2-/-
DLG2 +/+ DLG2 -/-
Relative X (µm)Relative X (µm)
R
e
la
ti
v
e
 Y
 (
µ
m
)
R
e
la
ti
v
e
 Y
 (
µ
m
)
DLG2-/-
A
Day 30 cortical differentiation Day 70 cortical differentiation
D
L
G
2
 +
/+
D
L
G
2
 -
/-
B C D
E
F G H
200
200
200
200
****
Day 30 Day 70
0
2
4
6
8
10
12
N
u
m
b
e
r 
S
e
c
o
n
d
a
ry
  
N
e
u
ri
te
s
**
**
Day 30 Day 70
0
100
200
300
400
500
600
700
800
T
o
ta
l N
e
u
ri
te
 L
e
n
g
th
(µ
m
)
Day 30 Day 70
0
25
50
75
100
125
S
o
m
a
 a
re
a
 (
µ
m
2
)
DLG2+/+
DLG2+/+ DLG2-/-
100µm 100µm
Figure 3
.CC-BY-NC-ND 4.0 International licenseauthor/funder. It is made available under a
The copyright holder for this preprint (which was not peer-reviewed) is the. https://doi.org/10.1101/2020.01.10.898676doi: bioRxiv preprint 
Figure 4
A 
9
8
7
6
5
4
3
2
1
0
Day 20 vs 15 Day 30 vs 20 Day 60 vs 30
-l
o
g
1
0
(P
G
W
A
S
)
Up
Down
E Regulator targets
Early
increasing-/-
(536)
TCF4 targets (direct) 2313544 2.39 0.33 6.01x10-5 0.000602.60x10-21 5.45x10-20
TBR1 targets (predicted) 55280 6.88 0.44 0.0039 0.0391.15x10-24 2.42x10
-23
FMRP targets 143816 7.10 0.34 0.00067 0.00679.14x10-59 1.92x10-57
BCL11B targets (predicted) 81695 3.81 0.39 0.0035 0.0352.52x10-20 5.28x10-19
CHD8 targets (indirect, up) 8562 0.40 1 1
CHD8 targets (indirect, down) 37315 3.60 -0.33 0.086 0.866.83x10-10 1.43x10-8
CHD8 midfoetal targets (direct) 882549 0.90 0.82 1
N N overlap OR P overlap P
corrected
ȕ P
corrected
overlap GWASPGWAS
TCF4 targets (direct)
TBR1 targets (predicted)
FMRP targets
BCL11B targets (predicted)
CHD8 targets (indirect, up)
CHD8 targets (indirect, down)
CHD8 midfoetal targets (direct)
306816 5.10 0.018 0.79 17.60x10-85 1.60x10-83
Regulator targets
Early
stable-/-      
(1713)
132
43
594
23
53
537
695
280
3544
562
315
2549
1.78
1.34
1.73
0.30
1.50
2.40
0.021
0.13
0.031
0.85
0.0079
0.52
1
0.079
1
2.92x10-8
0.051
7.87x10-23
1
0.0064
1.8x10-48
1.65x10-21
1
6.14x10-7
1
0.13
3.78x10-47
N N overlap OR P overlap P
corrected
ȕ P
corrected
overlap GWASPGWAS
TCF4 targets (direct)
TBR1 targets (predicted)
FMRP targets
BCL11B targets (predicted)
CHD8 targets (indirect, up)
CHD8 targets (indirect, down)
CHD8 midfoetal targets (direct)
49816 1 0.41 1
Regulator targets
Early
transient-/- 
(826)
31
8
200
13
19
231
695
280
3544
562
315
2549
0.75
0.47
0.97
0.40
1
1.87 0.050 0.49 1
0.95
0.99
0.67
1
0.46
8.05x10-14
1
1
1
1
1
1.69x10-12
N N overlap OR P overlap P
corrected
ȕ P
corrected
overlap GWASPGWAS
F GO Term N ȕ SE P Pcorrected
Calcium ion regulated exocytosis
Positive regulation of filopodium assembly
Glutamate receptor activity
Solute cation antiporter activity
Postsynaptic specialization membrane
Positive regulation of axon extension
-0.098
1.28
-0.57
0.32
0.64
0.62
1.48
-0.049
11
7
8
7
9
6
8
12
Membrane depolarization during action potential
Regulation of neurotransmitter secretion
0.36
0.48
0.45
0.38
0.42
0.42
0.44
0.30
0.79
0.0079
0.21
0.41
0.13
0.14
0.87
0.00072
1
0.13
1
1
1
1
1
0.011
Regulation of dendrite morphogenesis
Postsynaptic membrane
Axon guidance
Modulation of chemical synaptic transmission
Anterograde trans synaptic signaling
Presynapse
0.46
0.33
0.27
0.29
0.15
0.20
0.81
0.33
11
22
24
43
44
32
47
95
Somatodendritic compartment
Generation of neurons
0.35
0.28
0.24
0.18
0.17
0.21
0.18
0.12
0.19
0.23
0.25
0.11
0.37
0.35
0.0059
4.26x10-6
1
1
1
1
1
1
0.094
6.82x10-5
GWAS GWAS
ȕ
0.0025
0.23
0.0014
0.16
0.012
-0.014
-0.079
N
1348
526
181
1672
207
796
145
Gene expression profile
Late
Early-increasing-/-
Early-increasingWT only
Early-stable-/-
Early-stableWT only
Early-transient-/-
Early-transientWT only
SE
0.0031
0.051
0.086
0.029
0.076
0.040
0.097
C P
0.47
5.31x10-6
0.49
1.04x10-8
0.44
0.64
0.79
GWAS P
corrected
1
3.72x10-5
1
7.25x10-8
1
1
1
GWAS
ȕNNowakowski et al., 2017 SED P GWAS P
corrected
-0.00591555Latein vivo 0.030 0.58 1
0.25252Early-increasingin vivo 0.073 0.00024 0.00095
0.19234Early-stablein vivo 0.077 0.0059 0.023
0.047750Early-transientin vivo 0.040 0.12 0.47
GWAS
B 
Day 20 Day 30 Day 60
Early-increasing
Early-stable
Early-transient
Late
E
x
p
re
s
s
io
n
20-30
up
WT
20-30
up
WT and 30-60
up
WT
30-60
up
WT not 20-30
up
WT
20-30
up
WT not 20-60
up
WT
20-30
up
WT and 20-60
up
WT not 30-60
up
WT
(2058)
(2042)
(3624)
(3492)
(2122)
(2121)
(N gene)
Bonferroni 
P=0.05
.CC-BY-NC-ND 4.0 International licenseauthor/funder. It is made available under a
The copyright holder for this preprint (which was not peer-reviewed) is the. https://doi.org/10.1101/2020.01.10.898676doi: bioRxiv preprint 
Figure 5
L MD50 DLG2+/+ D60 DLG2+/+
D50 DLG2-/- D60 DLG2-/-
1 sec
1 sec
40 pA
C Percentage of cells firing APs
DLG2+/+ DLG2-/-
n=14
7%
36%57%
A Resting membrane potential
DLG2+/+ DLG2-/-
m
V
*
0
-20
-40
-60
-80
B Input resistance
DLG2+/+ DLG2-/-
G

2.0
1.5
1.0
0.5
0.0 n=15
20%
60%
20%
Train
Single
No AP
Train
Single
No AP
Active Non-active
DLG2+/+ DLG2-/-
D E AP height
m
V
DLG2+/+ DLG2-/-
**
0
20
40
60
80
F AP half-width
m
s
DLG2+/+ DLG2-/-
***
0
2
4
6
8
10
20mV
5ms
DLG2+/+ DLG2-/-
1s
120pA
-60pA
#! %$
"!! %&
0mV
-60mV
#! %$
"!! %&50mV
200ms
10
0.2
0.0
0.6
0.8
1.0
0.4
20 30 40 50 60 70 80 90 100
Amplitude (pA)
C
u
m
m
u
la
ti
v
e
 p
ro
b
a
b
ili
ty
DLG2+/+ DLG2-/-
60
50
40
30
20
10
0
A
m
p
lit
u
d
e
 (
p
A
)
0.0
0.2
0.6
0.8
1.0
0.4
10 20 30 40 50 60 70 80 90 100
Amplitude (pA)
C
u
m
m
u
la
ti
v
e
 p
ro
b
a
b
ili
ty
DLG2+/+ DLG2-/-
60
50
40
30
20
10
0
A
m
p
lit
u
d
e
 (
p
A
)
100
0.2
0.0
0.6
0.8
1.0
0.4
20 30 40 50 60 70 80
Inter-Event Interval (sec)
C
u
m
m
u
la
ti
v
e
 p
ro
b
a
b
ili
ty
DLG2+/+ DLG2-/-
0.5
0.4
0.3
0.2
0.1
0.0
F
re
q
u
e
n
c
y
 (
H
z
)
0.0
0.2
0.6
0.8
1.0
100 20 30 40 50 60 70 80
Inter-Event Interval (sec)
C
u
m
m
u
la
ti
v
e
 p
ro
b
a
b
ili
ty
DLG2+/+ DLG2-/-
2.5
2.0
1.5
1.0
0.5
0.0
F
re
q
u
e
n
c
y
 (
H
z
)
G Depolarisation 
įV/įt maximum
*
m
V
/m
s
0
50
100
150
m
V
/m
s
DLG2+/+ DLG2-/-
0
10
H Repolarisation
įV/įt maximum
**
20
30
I Spike threshold voltage
m
V
DLG2+/+ DLG2-/-
0
-10
-20
-30
-40
-50
J Rheobase current K Patch example
DLG2+/+ DLG2-/-
p
A
150
100
50
0
N OD50 DLG2
+/+ D60 DLG2+/+D50 DLG2-/- D60 DLG2-/-
DLG2+/+ DLG2-/-
D
L
G
4
 i
n
te
n
s
it
y
 
re
la
ti
v
e
to
 C
a
ln
e
x
in
DLG4
CANX
+/+ -/-
DLG4 in D65 synaptosomes
47%53% 47%53%39%61% 52%48%
0.0
0.2
0.4
0.6
n=34 n=36 n=31 n=30
40 pA
50 µm
.CC-BY-NC-ND 4.0 International licenseauthor/funder. It is made available under a
The copyright holder for this preprint (which was not peer-reviewed) is the. https://doi.org/10.1101/2020.01.10.898676doi: bioRxiv preprint 
N LoF intolerant = 3102
SZ LoF (de novo)
A 
C 
Late 
Early-increasing-/- 
Early-stable-/- 
Rate ratio (95% CI)
0.89 (0.55-1.38)
0.97 (0.54-1.62)
1.45 (1.11-1.87)
1.10 (0.73-1.60)
N observed
22
15
81
30Early-transient-/- 
P
0.75
1
0.005
0.62
P
corrected
1
1
0.021
1
SZ LoF singleton (case-control)D 
B Early-increasing-/- Early-stable-/- LoF intolerant
957
ȕ: 0.097
P: 0.0053
756
ȕ: 0.22
P: 5.82x10-8 ȕ: 0.057
P: 0.018
320
ȕ: 0.11
P: 0.041
ȕ: 0.093
P: 0.081
ȕ: -0.074
P: 0.93
216
ȕ: 0.39
P: 7.39x10-7
1841
289
537
Early-transient-/- 
Rate case
0.095
0.052
0.19
0.099
OR (95% CI)
0.91 (0.80-1.05)
1.28 (1.05-1.55)
1.26 (1.13-1.40)
1.09 (0.94-1.25)
Rate control
0.095
0.038
0.15
0.085
N case
386
214
795
403
Late 
Early-increasing-/- 
Early-stable-/- 
Early-transient-/- 
N control
545
219
836
484
P
corrected
0.77
0.052
0.00012
1
P
0.19
0.013
3.09x10-5
0.25
ORN overlap P overlap P
corrected
0.68221Late (1399) 1 1
2.66216Early-increasing-/- (536) 2.84x10-25 1.14x10-24
3.64756Early-stable-/- (1713) 2.38x10-119 9.54x10-119
2.14289Early-transient-/- (826) 5.60x10-22 2.24x10-21
  overlap
Figure 6
E 
G 
0
5
5
10
15
50
60
70
-l
o
g
1
0
(P
)
Early-transient-/- Early-stable-/- Early-increasing-/- Late
NDD
ASD
SZ
SIB
SZ
ADHD
BIP
AD
0.0
0.5
1.0
1.5
2.0
2.5
3.0
R
a
te
 r
a
ti
o
Early-transient-/- Early-stable-/- Early-increasing-/- Late
0.0
-0.05
0.05
0.10
0.15
0.20
0.25
ȕF
RH
IILF
LHQ
W
Early-transient-/- Early-stable-/- Early-increasing-/- Late
8
9
0
1
2
3
4
5
6
7
-l
o
g
1
0
(P
)
Early-transient-/- Early-stable-/- Early-increasing-/- Late
De novo LoF (P)
GWAS (P) H GWAS (Effect size)
F De novo LoF (Effect size)
Bonferroni P=0.05
Bonferroni P=0.05
.CC-BY-NC-ND 4.0 International licenseauthor/funder. It is made available under a
The copyright holder for this preprint (which was not peer-reviewed) is the. https://doi.org/10.1101/2020.01.10.898676doi: bioRxiv preprint 
Figure 7
A 
R
e
la
ti
v
e
 c
o
n
tr
ib
u
ti
o
n
Rare 
Severityhigh low
Genetic risk factors Common
ID/NDD ASD ADHD SZ BIP
Cognitive impairment
Psychopathology
Neurodevelopmental insult
B
Transcription regulation
Chromatin binding
Histone binding
Gene functions:
Reorganisation of 
transcriptional 
landscape
CHD8
*SETD1A
*
†
Mitochondrial energy production
Peptide synthesis + transport
Ion transport/homeostasis
Maintenance of neuronal signaling
Structure/connectivity
    - dendritic morphology
    - axon guidance
    - synaptogenesis
Migration
Differentiation
Cell projection development
*TRIO
*CACNA1G
*GRIA3
Initiation of neuronal 
differentiation and growth
†
TCF4
†
FMR1
Active properties
    - synaptic transmission
    - action potential generation
Terminal differentiation
Early-stable-/-
Gene functions:
Gene functions:
Early-increasing-/- Late
TBR1
BCL11B
†
CACNA1C
†
SCN2A
Gene functions:
G
e
n
e
 e
x
p
re
s
s
io
n
D20 D30 D60
Early-increasing
-/-
Late
Early-stable
-/-
Early-transient
-/-
Early-transient-/-
C 
D
L
G
2DLG2 independent
signalling
DLG2 dependent
signalling
Cell cycle 
exit
Neurogenic 
program activation
Cell growth
Migration
Active properties
Expression of 
cell-specific 
properties
DLG2 independent
signalling
DLG2 dependent
signalling
Cell cycle 
exit
Neurogenic 
program activation
Cell growth
Migration
Active properties
Delayed 
expression of 
cell-specific 
properties
Loss of DLG2
Genome-wide significant (P<2.2 x 10-6) in recent SCHEMA rare variant analyses (http://schema.broadinstitute.org/)
Rare variation causes Mendelian neurodevelopmental syndromes
Key regulators (arrows denote programs over-represented for known/predicted targets)
.CC-BY-NC-ND 4.0 International licenseauthor/funder. It is made available under a
The copyright holder for this preprint (which was not peer-reviewed) is the. https://doi.org/10.1101/2020.01.10.898676doi: bioRxiv preprint 
